

FORM PTO-1380 (Modified)  
(REV 11-2000)

## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371INTERNATIONAL APPLICATION NO  
PCT/JP00/04516INTERNATIONAL FILING DATE  
06 JULY 2000

ATTORNEY'S DOCKET NUMBER

217860US

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/030271

PRIORITY DATE CLAIMED  
08 JULY 1999 EARLIESTTITLE OF INVENTION  
APOPTOSIS-ASSOCIATED FACTORAPPLICANT(S) FOR DO/EO/US  
Osamu NODA, et al


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4.  The US has been elected by the expiration of 19 months from the priority date (Article 31).
5.  A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a.  is attached hereto (required only if not communicated by the International Bureau).
  - b.  has been communicated by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is attached hereto.
  - b.  has been previously submitted under 35 U.S.C. 154(d)(4).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a.  are attached hereto (required only if not communicated by the International Bureau).
  - b.  have been communicated by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
8.  An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4))
10.  An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11.  A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.  A copy of the International Search Report (PCT/ISA/210).

**Items 13 to 20 below concern document(s) or information included:**

13.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.  A **FIRST** preliminary amendment.
16.  A **SECOND** or **SUBSEQUENT** preliminary amendment
17.  A substitute specification.
18.  A change of power of attorney and/or address letter
19.  A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20.  A second copy of the published international application under 35 U.S.C. 154(d)(4).
21.  A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22.  Certificate of Mailing by Express Mail
23.  Other items or information:  
 Notice of Priority (2)  
 PCT/IB/308  
 Request for Consideration of Documents Cited in International Search Report  
 Sequence Listing (Pages i-11)

JC13 Rec'd PCT/PTO 08 JA

|  |   |   |                           |
|--|---|---|---------------------------|
| U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR<br><b>10/030271</b>   | INTERNATIONAL APPLICATION NO<br><b>PCT/JP00/04516</b> | ATTORNEY'S DOCKET NUMBER<br><b>217860US</b>   |                           |
| 24. The following fees are submitted:  |   | <b>CALCULATIONS PTO USE ONLY</b>  |                           |
| <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b>   |   |   |                           |
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....   |   | <b>\$1040.00</b>  |                           |
| <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....  |   | <b>\$890.00</b>   |                           |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....  |   | <b>\$740.00</b>   |                           |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....   |   | <b>\$710.00</b>   |                           |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....   |   | <b>\$100.00</b>   |                           |
| <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>  |   | <b>\$890.00</b>   |                           |
| Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).  |   | <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 <b>\$130.00</b>  |                           |
| <b>CLAIMS</b>  | <b>NUMBER FILED</b>                                   | <b>NUMBER EXTRA</b>   | <b>RATE</b>               |
| Total claims   | 52 - 20 =   | 32  | x \$18.00 <b>\$576.00</b> |
| Independent claims   | 4 - 3 =   | 1   | x \$84.00 <b>\$84.00</b>  |
| Multiple Dependent Claims (check if applicable).   |   | <input type="checkbox"/> <b>\$0.00</b>  |                           |
| <b>TOTAL OF ABOVE CALCULATIONS =</b>   |   | <b>\$1,680.00</b>   |                           |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.  |   | <b>\$0.00</b>   |                           |
| <b>SUBTOTAL =</b>  |   | <b>\$1,680.00</b>   |                           |
| Processing fee of <b>\$130.00</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).   |   | <input type="checkbox"/> 20 <input type="checkbox"/> 30    +  | <b>\$0.00</b>             |
| <b>TOTAL NATIONAL FEE =</b>  |   | <b>\$1,680.00</b>   |                           |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).  |   | <input type="checkbox"/> <b>\$0.00</b>  |                           |
| <b>TOTAL FEES ENCLOSED =</b>   |   | <b>\$1,680.00</b>   |                           |
|  |   | <b>Amount to be:<br/>refunded</b>   | <b>\$</b>                 |
|  |   | <b>charged</b>  | <b>\$</b>                 |
| a. <input checked="" type="checkbox"/> A check in the amount of <b>\$1,680.00</b> to cover the above fees is enclosed<br>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.<br>A duplicate copy of this sheet is enclosed.<br>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No <b>15-0030</b> . A duplicate copy of this sheet is enclosed.<br>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038 |   |   |                           |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.  |   |   |                           |
| SEND ALL CORRESPONDENCE TO:  |   |   |                           |
| 703-413-3000<br>703-412-2220   |   | SIGNATURE<br>   |                           |
| <br><b>22850</b>  |   | NAME<br><b>Norman F. Oblon</b><br>NAME<br><b>24,618</b><br>REGISTRATION NUMBER<br><b>11/8/02 James D Hamilton</b><br>DATE<br><b>Registration No. 26,421</b> |                           |

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

703-413-3000  
703-412-2220



22850

Page 2 of 2

217860US-0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF : :

TOSHIO OTA ET AL. : :

SERIAL NO: NEW U.S. PCT APPLN. : ATTN: APPLICATION BRANCH  
(Based on PCT/JP00/04516)

FILED: HEREWITH : :

FOR: APOPTOSIS-ASSOCIATED  
FACTOR

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicants submit herewith a Sequence Listing and a corresponding computer-readable Sequence Listing. Prior to examination on the merits, please amend the above-identified application as follows.

IN THE SPECIFICATION

Please amend the specification as follows:

Please replace the paragraph at page 27, lines 23-32, as follows:

A CDNA library was prepared from the NT-2 neuron progenitor cells (purchased from Stratagene), which is a teratocarcinoma cell derived from the fetal human testis and can differentiate into neurons by the treatment with retinoic acid. First, NT-2 cells were cultured without the induction by retinoic acid according to the manual supplied by the manufacturer, and then the cultured cells were harvested. Total RNA was extracted by the method described in the reference (J. Sambrook, E. F. Fritsch & T. Maniatis, Molecular Cloning

Second edition, Cold Spring Harbor Laboratory Press 1989). Poly(A)<sup>+</sup> RNA was further purified from the total RNA using oligo-dT cellulose.

Please replace line 8 on page 31 as follows:

[Example 3] Expression in various human tissue distribution

Please replace line 25 on page 31 as follows:

[Example 4] Functional analysis of NT2RM1000558

Page 39 (Abstract), after the last line, beginning on the next page, insert the Sequence Listing attached hereto.

#### IN THE CLAIMS

Please amend the claims as shown in the marked-up copy following this amendment to read as follow.

5. (Amended) A polynucleotide encoding a partial peptide of a protein encoded by the polynucleotide of claim 1.
9. (Amended) A protein encoded by the polynucleotide according to claim 1.
10. (Amended) A vector comprising the polynucleotide according to claim 1.
11. (Amended) A transformant retaining the polynucleotide according to claim 1.
12. (Amended) A method for producing the protein encoded by the polynucleotide of claim 1, said method comprising the steps of:
  - (1) culturing a transformant retaining the polynucleotide; and
  - (2) recovering the expression product.

13. (Amended) A polynucleotide comprising a polynucleotide complementary to the polynucleotide according to claim 1, or a complementary strand thereof, said polynucleotide being at least 15 bases long.

14. (Amended) An antibody against the protein encoded by the polynucleotide of claim 1.

15. (Amended) An immunological assay method comprising a step of observing an immunological reaction between the protein encoded by the polynucleotide of claim 1 and the antibody against said protein.

16. (Amended) A method for screening a substance regulating apoptosis, said method comprising the following steps of:

(1) contacting, with a candidate substance, cells expressing a protein encoded by the polynucleotide of claim 1; and

(2) culturing said cells under conditions inducing apoptosis to select a candidate substance that suppresses or promotes apoptosis.

18. (Amended) A method for regulating cell proliferation or cell death comprising administering the compound obtained by the method of claim 16 to a plurality of cells.

19. (Amended) A therapeutic agent for disorders characterized by cell proliferation or cell death, said agent comprising, as a principal ingredient, a compound obtained by the method of claim 16.

Please add the following new claims.

20. (New) A polynucleotide encoding a partial peptide of a protein encoded by the polynucleotide of claim 3.

21. (New) A protein encoded by the polynucleotide according to claim 3.

22. (New) A protein encoded by the polynucleotide according to claim 5.
23. (New) A protein encoded by the polynucleotide according to claim 6.
24. (New) A protein encoded by the polynucleotide according to claim 7.
25. (New) A vector comprising the polynucleotide according to claim 3.
26. (New) A vector comprising the polynucleotide according to claim 5.
27. (New) A vector comprising the polynucleotide according to claim 6.
28. (New) A vector comprising the polynucleotide according to claim 7.
29. (New) A transformant retaining the polynucleotide according to claim 3.
30. (New) A transformant retaining the polynucleotide according to claim 5.
31. (New) A transformant retaining the polynucleotide according to claim 6.
32. (New) A transformant retaining the polynucleotide according to claim 7.
33. (New) A transformant retaining the vector as claimed in claim 10.
34. (New) A method for producing the protein encoded by the polynucleotide of claim 3, said method comprising the steps of:
  - (1) culturing a transformant retaining the polynucleotide; and
  - (2) recovering the expression product.
35. (New) A method for producing the protein of claim 5, said method comprising the steps of:
  - (1) culturing a transformant retaining the polynucleotide; and
  - (2) recovering the expression product.
36. (New) A method for producing the protein of claim 6, said method comprising the steps of:
  - (1) culturing a transformant retaining the polynucleotide; and

(2) recovering the expression product.

37. (New) A method for producing the protein encoded by the polynucleotide of claim 7, said method comprising the steps of:

(1) culturing a transformant retaining the polynucleotide; and

(2) recovering the expression product.

38. (New) A polynucleotide comprising a polynucleotide complementary to the polynucleotide according to claim 3, or a complementary strand thereof, said polynucleotide being at least 15 bases long.

39. (New) A polynucleotide comprising a polynucleotide complementary to the polynucleotide according to claim 5, or a complementary strand thereof, said polynucleotide being at least 15 bases long.

40. (New) A polynucleotide comprising a polynucleotide complementary to the polynucleotide according to claim 6, or a complementary strand thereof, said polynucleotide being at least 15 bases long.

41. (New) A polynucleotide comprising a polynucleotide complementary to the polynucleotide according to claim 7, or a complementary strand thereof, said polynucleotide being at least 15 bases long.

42. (New) An antibody against the protein encoded by the polynucleotide of claim 3.

43. (New) An antibody against the protein encoded by the polynucleotide of claim 5.

44. (New) An antibody against the protein encoded by the polynucleotide of claim 6.

45. (New) An antibody against the protein encoded by the polynucleotide of claim 7.

46. (New) An immunological assay method comprising a step of observing an immunological reaction between the protein encoded by the polynucleotide of claim 3, and the antibody against said protein.

47. (New) An immunological assay method comprising a step of observing an immunological reaction between the protein encoded by the polynucleotide of claim 5, and the antibody against said protein.

48. (New) An immunological assay method comprising a step of observing an immunological reaction between the protein encoded by the polynucleotide of claim 6, and the antibody against said protein.

49. (New) An immunological assay method comprising a step of observing an immunological reaction between the protein encoded by the polynucleotide of claim 7, and the antibody against said protein.

50. (New) A method for screening a substance regulating apoptosis, said method comprising the following steps of:

(1) contacting, with a candidate substance, cells expressing a protein encoded by the polynucleotide of claim 3, and

(2) culturing said cells under conditions inducing apoptosis to select a candidate substance that suppresses or promotes apoptosis.

51. (New) A method for regulating cell proliferation or cell death comprising administering the compound obtained by the method of claim 17 to a plurality of cells.

52. (New) A therapeutic agent for disorders characterized by cell proliferation or cell death, said agent comprising, as a principal ingredient, a compound obtained by the method of claim 17.

REMARKS

Claims 1-52 are active in the present application. Claims 5, 9-16 and 18-19 have been amended to remove multiple dependencies and for clarity. Claims 20-52 are new claims. Support for the new claims is found in the original claims. No new matter is added.

Applicants have now submitted a Sequence Listing and a corresponding computer-readable Sequence Listing. Contents of the paper copy of the Sequence Listing and the computer-readable Sequence Listing are identical. Support for all the sequences listed in the Sequence Listing can be found in the present application. No new matter is introduced by the submission of the Sequence Listing and the computer-readable Sequence Listing.

Applicants submit that this application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Stefan U. Koschmieder, Ph.D.  
Registration No. 50,238



**22850**

(703) 413-3000  
NFO/DJP/smi

I:\atty\Twb\217860USOPCT-PR.wpd

217860US-0PCT

|                       |
|-----------------------|
| <b>Marked-Up Copy</b> |
| Serial No:            |
| Amendment Filed on:   |
| <u>01-08-02</u>       |

IN THE SPECIFICATION

Please amend the specification as follows:

Please replace the paragraph at page 27, lines 23-32, as follows:

--A CDNA library was prepared from the NT-2 neuron progenitor cells (purchased from Stratagene), which is a teratocarcinoma cell derived from the fatal human testis and can differentiate into neurons by the treatment with retinoic acid. First, NT-2 cells were cultured without the induction by retinoic acid according to the manual supplied by the manufacturer, and then the cultured cells were harvested. [mRNA] Total RNA was extracted by the method described in the reference (J. Sambrook, E. F. Fritsch & T. Maniatis, Molecular Cloning Second edition, Cold Spring Harbor Laboratory Press 1989). Poly(A)<sup>+</sup> RNA was further purified from the [mRNA] total RNA using oligo-dT cellulose.--

Please replace line 8 on page 31 as follows:

--[Example [4]3] Expression in various human tissue distribution--

Please replace line 25 on page 31 as follows:

--[Example [5]4] Functional analysis of NT2RM1000558--

IN THE CLAIMS

Please amend the claims as follows.

--5. (Amended) A polynucleotide encoding a partial peptide of a protein encoded by the polynucleotide of [claims 1 or 3] claim 1.

9. (Amended) A protein encoded by the polynucleotide according to [any one of claim 1, claim 3, claim 5, claim 6, and claim 7] claim 1.

10. (Amended) A vector comprising the polynucleotide according to [any one of claim 1, claim 3, claim 5, claim 6, and claim 7] claim 1.

11. (Amended) A transformant retaining the polynucleotide according to [any one of claim 1, claim 3, claim 5, claim 6, and claim 7, or the vector of claim 10] claim 1.

12. (Amended) A method for producing the protein encoded by the polynucleotide of claim [9] 1, said method comprising the steps of:

- (1) culturing [the] a transformant [of claim 11] retaining the polynucleotide; and
- (2) recovering the expression product.

13. (Amended) A polynucleotide comprising a polynucleotide complementary to the polynucleotide according to [any one of claim 1, claim 3, claim 5, claim 6, and claim 7] claim 1 or a complementary strand thereof, said polynucleotide being at least 15 bases long.

14. (Amended) An antibody against the protein encoded by the polynucleotide of claim [9] 1.

15. (Amended) An immunological assay method comprising a step of observing an immunological reaction between the protein encoded by the polynucleotide of claim [9] 1 and the antibody [of claim 14] against said protein.

16. (Amended) A method for screening a substance regulating apoptosis, said method comprising the following steps of:

- (1) contacting, with a candidate substance, cells expressing a protein encoded by the polynucleotide of claim 1 [or claim 3]; and
- (2) culturing said cells under conditions inducing apoptosis to select a candidate substance that suppresses or promotes apoptosis.

18. (Amended) A method for regulating cell proliferation or cell death comprising administering the compound [Use of a compound that can be] obtained by the method of claim 16 to a plurality of cells [or claim 17, in regulation of cell proliferation or cell death].

19. (Amended) A therapeutic agent for disorders characterized by cell proliferation or cell death, said agent comprising, as a principal ingredient, a compound [that can be] obtained by the method of claim 16 [or claim 17].

Claims 20-52 (New).--

DOCKET NO.: 217860US0XPCT

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

IN RE APPLICATION OF :

Toshio OTA, et al. : ATTN: Box Sequence/Application Branch

SERIAL NO: 10/030,271 :

FILED:January 8, 2002 :

FOR: APOPTOSIS-ASSOCIATED FACTOR



**PRELIMINARY AMENDMENT AND STATEMENT**

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Responsive to the Notice dated March 28, 2002, Applicants submit herewith a substitute Sequence Listing and a corresponding Computer Readable Sequence Listing.

**IN THE SPECIFICATION**

After page 39 (Abstract), beginning on a new page, please delete the original Sequence Listing from page 1 to 10 and insert the substitute Sequence Listing attached hereto.

**REMARKS**

Claims 1-19 are pending in the present application.

The specification has been amended to insert a substitute Sequence Listing. In addition, a Computer Readable Sequence Listing (CRF) is attached herewith. The contents of

the paper copy of the substitute Sequence Listing and the contents of the (CRF) submitted herewith are identical. Support for all the sequences listed in the substitute Sequence Listing can be found in the present application as originally filed. No new matter is introduced by the submission of the substitute Sequence Listing.

Applicants submit that the present application is now in condition for examination on the merits. Early notice to this effect is earnestly solicited.

Respectfully submitted,  
OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No.: 24,618



**22850**

TEL: (703) 413-3000  
FAX: (703)413-2220

James J. Kelly, Ph.D.  
Registration No.: 41,504

NFO/JK/TWB/sjh  
E:\atty\Twb\217860US-PR.WPD

DOCKET NO.: 217860US0XPCT  
SERIAL NO.: 10/030,271

**MARKED-UP COPY OF**  
**PRELIMINARY AMENDMENT**

**IN THE SPECIFICATION**

After page 39 (Abstract), beginning on a new page, please delete the original Sequence Listing from page 1 to 10 and insert the substitute Sequence Listing attached hereto.

**DESCRIPTION****APOPTOSIS-ASSOCIATED FACTOR****5    Technical Field**

The present invention relates to an apoptosis-associated factor.

**Background Art**

10           Apoptosis was once referred to as a programmed cell death. To survive, multicellular organisms require mechanisms to remove unwanted or unnecessary cells from living bodies thereof. Apoptosis has been understood as a pre-programmed cell death to remove cells, which have become unnecessary in the development process or alteration  
15          of generations of cells. In cells in which apoptosis has been induced, nuclear shrinkage and DNA fragmentation are observed, followed by the cell retraction with plasma membrane left intact. *In vivo*, the retracted cells are then eliminated by macrophages. In contrast to apoptosis, cell death referred to as necrosis is accompanied with  
20          the destruction of cell structure. Therefore, apoptosis whereby cells die out by themselves is often referred to as a "clean cell death".

Later, it has become known that a similar cell death as that observed in the developing process is induced by extracellular  
25          stimulus. For example, TNF and Fas are typical cytokines that induce apoptosis. Apoptosis is also induced by stimulus such as irradiation of ultraviolet ray or radiation, exhaustion of cell growth factors, or activation of certain cancer genes. Disorders such as autoimmune disorders and cancer have become understood as the results of failure  
30          to perish harmful cells due to the dysfunction of apoptosis.

By recent successive findings of various apoptosis-associated molecules, a general image of apoptosis has been gradually elucidated. However, mechanisms of apoptosis are still not elucidated.

At present, the intracellular process from response to outside  
35          stimulus to apoptosis has been described generally as follows. That is, it has been revealed that the caspase family activated by a variety

of causes brings about cell death. It has been found that caspases include a number of enzymes having different substrate specificities, so that a group of these caspases has been generically called "caspase family". The caspase family is classified into three large groups 5 based on the substrate specificity. Among them, the group 2 caspase is said to be involved in executing apoptosis. The group 3 caspase is activated in response to extracellular stimulus in upstream of the apoptosis execution cascade, functioning to activate the group 2 caspase located further downstream thereof. On the other hand, 10 the group 1 caspase is thought to have the function to promote the production and secretion of cytokines. Caspases classified into groups 2 and 3 as well as amino acid sequences recognized by them are shown below:

Group 2

|    |           |      |
|----|-----------|------|
| 15 | Caspase-2 | DEHD |
|    | Caspase-3 | DEVD |
|    | Caspase-7 | DEVD |

Group 3

|    |           |      |
|----|-----------|------|
| 20 | Caspase-6 | VEHD |
|    | Caspase-8 | LETD |
|    | Caspase-9 | LETD |

Group 3 caspases are activated by binding of a ligand to the Fas and TNF receptors, and then, cleave group 2 caspases to activate them, resulting in transduction of signals to further downstream.

25 Such signal transduction is referred to as "apoptosis execution cascade". In downstream of the apoptosis execution cascade, a variety of factors transmitted signals are suspected to function as the execution team to cause cell death. However, many problems remain to be solved about which factors actually cause cell death. 30 For example, it has been demonstrated that certain caspase degrades a nuclease inhibitor ICAD (inhibitor of CAD) and then, nuclease CAD (Caspase Activated DNase) is allowed to transfer to the nuclear, followed by initiating the cleavage of chromosomal DNA characteristic of apoptosis (Enari, M. et al., Nature, 391: 43-50, 1998).

35 Thus, many molecules having critical functions in carrying out apoptosis are thought to be included in factors constituting the

downstream of apoptosis execution cascade. These factors may become important targets in the control of apoptosis.

Disclosure of the Invention

5 An object of the present invention is providing a novel apoptosis-associated factor.

In order to isolate novel human genes, the present inventors isolated many full-length cDNA clones from a human cDNA library prepared by the oligo-capping method, and then, analyzed these 10 full-length cDNA clones for the apoptosis-associated genes based on sequence alignment. As a result, the present inventors have found that one of these full-length cDNA clones, NT2RM1000558, comprises Death Effector Domain (DED) motif and a cleavage recognition sequence for the caspase family both of which have been said to be important 15 for the apoptotic signal transduction. This full-length cDNA clone is a gene cloned from a cDNA library of NT-2 neuron precursor cells.

NT2RM1000558 encodes a protein comprising 326 amino acid residues. Considering the amino acid sequence analysis thereof, the digestion at the cleavage recognition sequence for the caspase 20 family is thought to remove 23 amino acid residues at the C-terminus yielding a protein comprising 303 amino acid residues. Furthermore, motifs were found in the protein of the present invention such as DED at positions 26-103, and the Nuclear Localization Signals (NLSs) at positions 100-109 as well as positions 152-174, etc.

25 On the other hand, a protein designated DEDD (Alexander H. Stegh et al. 1998, The EMBO Journal Vol. 17 No. 20, 5974-5986; Chandra P. Leo et al. 1998, Endocrinology Vol. 139 No. 12, 4838-4848) are known. DEDD is a protein comprising 318 amino acid residues, which has a similar structure to that of the apoptosis-associated factor 30 of the present invention in that DEDD comprises DED, NLS, and caspase digestion domain. However, comparison of amino acid sequences of the similar DED in both proteins (DEDD: SEQ ID NO: 9) revealed only a 43% homology between them, indicating that these two proteins are clearly different proteins. Furthermore, a role of DEDD in the apoptosis execution cascade has not been fully elucidated.

35 Next, the present inventors confirmed activities of a protein

comprising 326 amino acid residues (SEQ ID NO: 4) encoded by NT2RM1000558 and a protein resulted from its digestion comprising 303 amino acid residues (SEQ ID NO: 2). As a result, apoptosis-inducing activity in the protein comprising 326 amino acid residues was not observed, in contrast to clear apoptosis-inducing activity in the protein comprising 303 amino acid residues was observe. The present invention is achieved based on such discovery. That is to say, the present invention specifically relates to the following proteins, DNAs, and the use thereof:

10 [1] a polynucleotide encoding a protein having apoptosis-inducing activity, said polynucleotide selected from the group consisting of the following (a) to (d):

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1;

15 (b) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 2;

(c) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 2 in which one or more amino acids are substituted, deleted, inserted, and/or added; and

20 (d) a polynucleotide hybridizing under stringent conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1;

[2] the polynucleotide of [1], said polynucleotide having 60% or more homology to the nucleotide sequence of SEQ ID NO: 1;

25 [3] a polynucleotide encoding a precursor of a protein having apoptosis-inducing activity, said polynucleotide selected from the group consisting of the following (e) to (h):

(e) a polynucleotide comprising a protein coding region of the nucleotide sequence of SEQ ID NO: 3;

30 (f) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 4;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 4 in which one or more amino acids are substituted, deleted, inserted, and/or added; and

35 (h) a polynucleotide hybridizing under stringent conditions with a polynucleotide comprising the nucleotide sequence of

SEQ ID NO: 3;

[4] the polynucleotide of [3], said polynucleotide having 60% or more homology to the nucleotide sequence of SEQ ID NO: 3;

5 [5] a polynucleotide encoding a partial peptide of a protein encoded by the polynucleotide of [1] or [3];

[6] a polynucleotide encoding molecular-evolutionarily the same gene as a gene comprising the nucleotide sequence of SEQ ID NO: 3;

10 [7] a polynucleotide encoding a protein that comprises the amino acid sequence of SEQ ID NO: 4 in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a character dominant negative to that of a protein comprising the amino acid sequence of SEQ ID NO: 4;

15 [8] the polynucleotide of [7], said polynucleotide encoding the amino acid sequence of SEQ ID NO: 4 in which the amino acid sequence at position 300 to 303 has been modified to a caspase-resistant amino acid sequence;

[9] a protein encoded by the polynucleotide according to any one of [1], [3], [5], [6], and [7];

20 [10] a vector comprising the polynucleotide according to any one of [1], [3], [5], [6], and [7];

[11] a transformant retaining the polynucleotide according to any one of [1], [3], [5], [6], and [7], or the vector of [10];

[12] a method for producing the protein of [9], said method comprising the steps of:

25 culturing the transformant of [11]; and  
recovering an expression product;

[13] a polynucleotide comprising a polynucleotide complementary to the polynucleotide according to any one of [1], [3], [5], [6], and [7] or a complementary strand thereof, said polynucleotide being at least 15 bases long;

[14] an antibody against the protein of [9];

[15] an immunological assay method comprising a step of observing an immunological reaction between the protein of [9] and the antibody of [14];

35 [16] a method for screening a substance regulating apoptosis, said method comprising the following steps of:

(1) contacting, with a candidate substance, cells expressing a protein encoded by the polynucleotide of [1] or [3]; and  
5 (2) culturing said cells under conditions inducing apoptosis to select a candidate substance that suppresses or promotes apoptosis;

[17] a method for screening a substance regulating apoptosis, said method comprising the following steps of:

10 (1) contacting, with a candidate substance, cells into which a vector comprising an expression control region for a gene comprising the nucleotide sequence of SEQ ID NO: 3 and a reporter gene operably linked downstream thereof has been introduced;  
15 (2) measuring activity of said reporter gene; and  
 (3) selecting a candidate substance that increases or decreases the reporter gene activity in the step (2) compared with a control;

[18] use of a compound that can be obtained by the method of [16] or [17], in regulation of cell proliferation or cell death; and  
20 [19] a therapeutic agent for disorders characterized by cell proliferation or cell death, said agent comprising, as a principal ingredient, a compound that can be obtained by the method of [16] or [17].

The present invention relates to a novel polynucleotide encoding a protein having apoptosis-inducing activity. Nucleotide sequences of polynucleotides derived from human included in the polynucleotide according to the present invention are described in SEQ ID NO: 1 or 3. Amino acid sequences of proteins encoded by the polynucleotides of the present invention are also indicated in SEQ ID NO: 2 or 4. There is no particular limitation on forms of polynucleotides of the present invention as long as they can encode the protein of the present invention, which include genomic DNAs, chemically synthesized DNAs, RNAs, and so forth as well as cDNAs. Also, polynucleotides having any nucleotide sequences on which genetic codes are degenerated may be included as long as they can encode the protein of the present invention. In addition, the polynucleotide of the present invention may be fused with a

polynucleotide encoding other protein and oligopeptide. Polynucleotides encoding proteins of the present invention can be isolated as described above, by the standard methods such as the hybridization method using the nucleotide sequence described in SEQ 5 ID NO: 1 or 3, or a portion thereof as a probe, and the PCR method using a primer designed based on the information of these nucleotide sequences.

The protein of the present invention comprising the amino acid sequence described in SEQ ID NO: 2 shows apoptosis-inducing activity 10 in mammalian cells. In contrast, the protein comprising the amino acid sequence described in SEQ ID NO: 4 does not shows apoptosis-inducing activity in mammalian cells. The amino acid sequence described in SEQ ID NO: 4 comprises, at positions 300 to 303 from the N-terminus, the amino acid sequence (DEAD) which 15 corresponds to the Caspase Cleavage Domain. The amino acid sequence described in SEQ ID NO: 2 corresponds to that of a protein produced when the protein comprising the amino acid sequence described in SEQ ID NO: 4 is cleaved in this Caspase Cleavage Domain. Therefore, 20 in the present invention, a protein having apoptosis-inducing activity is referred to as the "active form". On the other hand, a protein such as that comprising the amino acid sequence described in SEQ ID NO: 4, which produces the active form via a certain process but has no apoptosis-inducing activity in itself is also included 25 in the present invention. Such protein is referred to as the "inactive form" in the present invention. Inactive form proteins in the present invention may be defined as proteins which can produce active form proteins with protease such as caspase or by the chemical treatments.

The Caspase Cleavage Domain found in the amino acid sequence described in SEQ ID NO: 4 comprises the amino acid sequence DEAD. 30 Caspases recognizing this amino acid sequence are Caspase-3 and Caspase-7 in human. Caspase-3 and Caspase-7 belong to the group 3 caspases, constituting downstream of apoptosis execution cascade. Consequently, the active form of the protein of the present invention may be involved in important processes for the progression of 35 apoptosis execution cascade, triggered by a variety of causes at downstream thereof. Therefore, the regulation of apoptosis may be

achieved by controlling the production of the protein of the present invention or action thereof. That is to say, the present invention relates to a substance that can regulate apoptosis and a method for screening said substance. Apoptosis can be controlled with a 5 substance that can regulate the production of the protein of the present invention or the action thereof. Such substance can be isolated by a screening method as described below.

More specifically, the inhibition of *in vivo* production of the above-described active form protein can result in the effective 10 suppression of apoptosis progression. Alternatively, the suppression of apoptosis can be achieved by inhibiting the function of the active form protein. Expression inhibition of the above-described protein can be achieved using an antisense nucleic acid drug or a decoy nucleic acid after the transcriptional control 15 region for the expression of the protein has been elucidated. The function of active form protein per se is effectively inhibited by altering the tertiary structure of the active site of the protein through the administration of a compound binding to the protein, or interfering with the binding of the active form protein to its 20 target compound. Alternatively, functions of the protein of the present invention can be reduced by the dominant negative effect.

In contrast, the stimulation of the production or the activity 25 of the above-described protein in particular cells can induce apoptosis in the cell. For example, if the production of the protein can be specifically induced in cancer cells, the cancer treatment may be safely performed. Specifically, a cancer treatment based on the present invention can be performed by inducing the expression 30 of the gene of the apoptosis-associated factor of the present invention in cancer cells, or introducing the gene encoding the active form protein together with a promoter expressing specifically in cancer cells thereto. Alternatively, a protein useful in the cancer treatment can be also obtained by modifying the Caspase Cleavage Domain in the amino acid sequence of the inactive form protein according to the present invention with the amino acid sequence 35 specifically recognized by a protease which is highly expressed in cancer cells. Such proteins can be used as safe drugs producing

the active form protein only in cancer cells.

Furthermore, using the protein of the present invention, it is possible to obtain a novel factor associated with this protein-mediated apoptosis. For example, as in the case of the binding of the Fas-associated death domain protein (FADD) to Caspase-8, the binding of a protein having the Death Effector Domain (DED) to a factor is carried out mediated by binding between respective DEDs. Thus, a novel factor having DED, which binds to the protein of the present invention, can be obtained by utilizing DED of the protein.

10 Specifically, by using the yeast two-hybrid system (A novel genetic system to detect protein-protein interactions. Fields, S. and Song, O. (1989) Nature 340: 245-246) with DED of the protein of the present invention as a bait, a novel factor having DED which binds to DED of the protein of the present invention can be obtained from cDNA libraries derived from mammalian cells and tissues.

Furthermore, for example, by using the inactive form protein according to the present invention, a novel caspase that recognizes the caspase cleavage domain thereof can be also obtained. Specifically, first, a labeled inactive form protein as a substrate is reacted with a protein solution containing activated caspases. Subsequently, these caspases can be isolated by detecting the conversion to the active form protein from the inactive form protein of the present invention as an indicator in the reaction solution using SDS-PAGE, etc. Since the protein of the present invention is a novel protein, a caspase which digests the protein may be a novel caspase other than Caspase-3 and Caspase-7.

Alternatively, when the active form protein of the present invention causes apoptosis in conjunction with other factors, these factors can be isolated using the active form protein of the present invention. Examples of these factors may be proteins such as FADD and Caspase-8 which serve as factors playing the critical role for inducing the function of the apoptosis signal by CD95 (Fas). Such novel proteins having DED and involving in the apoptosis signal can be isolated by measuring apoptosis in mammalian cells such as HEK293T cells, induced by coexpression of the proteins with the active form protein of the present invention.

The protein of the present invention can be prepared as a recombinant protein or a natural protein. For example, a recombinant protein can be prepared by introducing a vector containing a DNA insert encoding the protein of the invention into an appropriate host, and purifying the expressed products from the transformant, as described below. Alternatively, it is possible to prepare the protein of the invention by *in vitro* translation ("On the fidelity of mRNA translation in the nuclease-treated rabbit reticulocyte lysate system." Dasso M.C., and Jackson R.J. (1989) Nucleic Acids Res. 17: 3129-3144). On the other hand, a natural protein can be prepared, for example, by utilizing an affinity column which is bound with the antibody against the protein of the invention, as described below ("Current Protocols in Molecular Biology" Ausubel et al. edit. (1987) John Wiley & Sons, Section 16.1-16.19). The antibody used in the preparation of an affinity column can be a monoclonal antibody or polyclonal antibody.

In addition, the present invention includes a polynucleotide encoding a protein functionally equivalent to the protein comprising the amino acid sequence described in SEQ ID NO: 2 or 4. Herein, the term "functionally equivalent" means that a subject protein is functionally equivalent to the active form protein of the present invention when the protein has an activity to induce apoptosis. Alternatively, a protein which can result in the active form protein having apoptosis-inducing activity through certain processes is functionally equivalent to the inactive form protein of the present invention. The process to produce the active form protein from the inactive form protein is not limited. For example, when a protein comprising the amino acid sequence described in SEQ ID NO: 4 is used, the digestion at the caspase cleavage domain thereof is required for the production of the active form protein. Substitution of this domain with the recognition sequences of other caspases or further proteases other than caspases may result in inactive form proteins producing active form proteins by the action of corresponding enzymes. Apoptosis-inducing activity can be confirmed, for example, by the expression of a gene encoding the protein in mammalian cells and the observation of apoptosis in the cells as described in the working

examples. Apoptosis can be found by considering morphological changes of cells and chromosomal DNA fragmentation as an indicator.

One skilled in the art would be able to prepare proteins functionally equivalent to the proteins identified in the working examples below, for example, by using a method for introducing mutations into the amino acid sequences of proteins (e.g. site-directed mutagenesis, Current Protocols in Molecular Biology edit. Ausubeletal. (1987) Publish. JohnWiley & Sons Section 8.1-8.5). Such proteins might occur due to spontaneous mutation of amino acids in nature. The present invention also includes a protein having an amino acid sequence in which one or several amino acid residues are different from those found in a sequence of any one of the proteins identified in the working examples below (SEQ ID NO: 2 or 4) due to a substitution, deletion, insertion and/or addition, as long as the protein retains a function equivalent to the proteins identified in the working examples below.

Number or sites of amino acid mutations in the protein are not limited, as long as the protein function is retained. The number (percentage) of mutations is typically 10% or less, preferably 5% or less, and more preferably 1% or less of the total amino acids. Preferably, in view of maintaining protein function, substituting amino acids may have properties similar to the amino acids to be substituted. For example, Ala, Val, Leu, Ile, Pro, Met, Phe, and Trp are all classified into nonpolar amino acids, and they are thought to share common properties. Uncharged amino acids include Gly, Ser, Thr, Cys, Tyr, Asn, and Gln. Acidic amino acids include Asp and Glu, and basic amino acids include Lys, Arg, and His.

Alternatively, a protein functionally equivalent to the protein identified in the working examples below can be isolated using a hybridization or gene amplification technique well known to oneskilledintheart. Morespecifically, using the hybridization technique (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 6.3-6.4), one skilled in the art would routinely be able to isolate a polynucleotide showing a significant homology to any one of the polynucleotide sequences encoding the proteins identified in the working examples below (SEQ

ID NO: 1 or 3) by using a polynucleotide sequences, or a portion thereof, and obtain a functionally equivalent protein from the polynucleotide isolated. The present invention includes a protein encoded by a polynucleotide hybridizing to a polynucleotide encoding a protein identified in the working examples below, as long as the proteins are functionally equivalent. A functionally equivalent protein can be isolated from animals including, but not limited to, vertebrates such as humans, mice, rats, rabbits, pigs, and cattle. From these animals, one can isolate genes that originated from molecular-evolutionarily the same gene that encodes an apoptosis-associated factor of the present invention. As used herein, the term "genes that originated from molecular-evolutionarily the same gene" refers to genes that are rationally judged to have evolved from one ancestor gene from which the human gene of the present invention evolved in the course of molecular-evolution. This judgment is based on polynucleotide sequence analysis of the genes or analysis of their physiological roles and such. Such genes maintain a significant nucleotide sequence homology among them.

Stringent hybridization conditions for isolating a polynucleotide encoding a functionally equivalent protein are, typical washing conditions such as "1x SSC, 0.1% SDS, 37 °C". More stringent conditions are, for example, "0.5x SSC, 0.1% SDS, 42°C", and even more stringent conditions are, for example, "0.1x SSC, 0.1% SDS, 65°C". The more stringent the hybridization conditions become, the more homologous to the probe sequence the polynucleotide is expected to be. Note that the above combinations of SSC, SDS, and temperature are given only for illustration, and one skilled in the art can achieve the same level of stringency by combining these factors appropriately to determine the hybridization conditions. The factors include those described above, or other factors (e.g. probe concentrations, length of probes, reaction time, etc.).

In general, a protein isolated using such hybridization techniques shows a significant homology in the nucleotide sequence encoding the protein, or in its amino acid sequence, compared to the sequence of a protein of the present invention, shown in SEQ

ID NO: 2 or 4. "Significant homology" refers to a sequence identity of at least 60% or more, preferably 70% or more, more preferably 80% or more (e.g. 90% or more). Sequence homology can be determined using the BLAST 2 search algorithm (Altschul, S.F. et al, 1997, Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25: 3389-3402).

5 A gene-amplification technique (PCR) (Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 6.1-6.4)) can be used to design primers based on a  
10 part of any of the polynucleotide sequences identified in the working examples below (SEQ ID NO: 1 or 3), and to isolate a polynucleotide fragment that shows a significant homology to the above polynucleotide sequence or a portion thereof, to obtain a protein functionally equivalent to the protein identified in the working examples.

15 Alternatively, the present invention relates to a DNA encoding a protein having a character dominant negative to that of the protein of the present invention. A polynucleotide encoding a protein having a dominant negative character has the function to delete or reduce the activity of endogenous wild-type protein inherent in cells by  
20 the expression thereof. For example, substitution of the region corresponding to the DEAD sequence in the apoptosis-associated factor of the present invention with an amino acid sequence which is not cleaved by caspase can result in an inactive protein which never produces the active form protein. Expression of a gene encoding  
25 such amino acid sequence in cells suppresses the expression of apoptosis-associated factor of the present invention by the dominant negative effect (competitive inhibition of the inactive form). Therefore, the progression of apoptosis can be inhibited by introducing patients having the above-described disorders with a  
30 gene encoding the inactive form protein to express using gene transfer technique with virus vectors, etc.

The present invention also provides partial peptides of the protein of the present invention. These partial peptides are useful as the immunogen to obtain antibodies for the protein of the present invention. In particular, a partial peptide comprising an amino acid sequence specific to the protein of the present invention with

low homology to other proteins is expected as the immunogen to yield antibody with a high specificity to the protein of the present invention.

In addition, partial peptides of the apoptosis-associated factor of the present invention or its inactive form protein include partial peptides containing, for example, DED, which is a highly conserved amino acid sequence found among a number of apoptosis-associated factors. DED corresponds to 78 amino acid residues at positions 26 to 103 of the protein (common in both the active and inactive forms) of the present invention. Since DED has been shown to be a region responsible for the signal transduction in the apoptosis execution cascade, this region is thought to play an important role also in the maintenance of the activity of the protein of the present invention. In addition, the nuclear localization signal (NLS) domain found in the protein of the present invention may also be an important portion to support the activity thereof. Therefore, a peptide containing this region is useful as a target for screening compounds that modify the activity of this protein.

A partial peptide of the present invention comprises at least 7 amino acid residues, preferably 9 or more amino acid residues, more preferably 12 or more amino acid residues, even more preferably 15 or more amino acid residues. The partial peptide of the present invention may be produced by, for example, genetic engineering, a well-known technique for peptide synthesis, or cleavage of the proteins of the present invention with an appropriate peptidase.

The present invention also provides expression vectors comprising any one of the polynucleotides mentioned above. Furthermore, the present invention relates to polypeptides mentioned above, transfectants harboring any of the expression vectors mentioned above, and a method for producing an apoptosis-associated factor or a partial peptide thereof. Such a method comprises culturing a transfector and isolating a protein of the present invention from the culture. Moreover, the present invention provides the protein or partial peptide produced by the above method.

When producing polypeptides by means of genetic recombination, the type and extent of glycosylation of a polypeptide of interest

would differ depending on the type of host cell. Furthermore, in the method of so-called "secretory production" of polypeptides, it is well known to one skilled in the art that (N- and/or C-) terminal amino acid sequences of precursor peptides expressed in host cells 5 would undergo processing by signal peptidases and such to produce polypeptides having various terminal sequences. Therefore, one skilled in the art would easily understand that such polypeptides are also included in the proteins of the present invention.

The working example described below illustrates only an example 10 of constructing a vector that functions in mammalian cells as an expression vector. However, since the polynucleotide sequences encoding the proteins of the present invention are disclosed herein, it would be easy for one skilled in the art to construct an expression vector that can express and produce a protein of the present invention 15 when such a vector is introduced into a fungal host cell, such as a yeast, or a prokaryotic host cell. Therefore, the present invention includes expression vectors constructed using any methods known in the art based on the polynucleotide sequences of the present invention.

20 Microbial cells that can be used for the expression of the polynucleotides encoding the proteins of the present inventions include, for example, prokaryotic bacteria (e.g. *Escherichia coli* and *Bacillus subtilis*) and eukaryotic yeasts (e.g. *Saccharomyces cerevisiae*). Mammalian cells include cultured human cells and cultured animal cells. Moreover, cultured plant cells can be used. 25

Examples of microorganisms include bacteria of the genus *Escherichia* and baker's yeast. More specifically, the host microorganism includes, for example, the following strains:

bacteria belonging to the genus *Escherichia*

30       *E. coli* HB101 (ATCC 33694),  
          *E. coli* HB101-16 (FERM BP-1872),  
          *E. coli* MM294 (ATCC 31446),  
          *E. coli* DHL (ATCC 33849), etc.; and

Baker's yeast

35       *S. cerevisiae* AH22 (ATCC 38626), etc.

Examples of mammalian cells include HEK293 cells derived from

human embryonic kidney cells, mouse L929 cells, Chinese hamster ovary (CHO) cells, etc.

Generally, expression vectors are constructed with, at least, a promoter, an initiation codon, a polynucleotide encoding the amino acid sequence of any of the proteins of the present invention, a termination codon, and a self-replication unit, when prokaryotes, bacteria, particularly E. coli are used as host cells. When eukaryotic cells such as yeast and mammalian cells are used, expression vectors are preferably constructed with, at least, a promoter, an initiation codon, a polynucleotide encoding the amino acid sequence of any of the proteins of the present invention, and a termination codon. Additionally, an enhancer sequence, 5'- and 3'-untranslated regions for the proteins of the present invention, a polyadenylation site, and a self-replication unit may be integrated.

The self-replication unit preferably comprises a selectable marker for transfecteds (e.g. resistance to ampicillin). In the case of expression vectors using bacteria as host cells, the term "promoter" means a promoter-operator region containing a promoter, operator, and a Shine-Dalgarno (SD) sequence (e.g. AAGG, etc.). Examples of such promoters include conventional promoter-operator regions (e.g. the lactose operon, PL-promoter, trp-promoter, etc.). An Example of a promoter for expression vectors used in yeast host cells includes the pho5 promoter. Additionally, to facilitate purification, basic amino acids having affinity for chelated metal ions can be added to either end of a protein of the present invention.

When basic amino acids are added, a primer having, at its 5'-end, a nucleotide sequence sequentially coding for desired amino acid residues can be used for PCR to introduce an oligonucleotide at either end of a gene of interest. Histidine, lysine, arginine, and such can be used as basic amino acids.

Examples of promoters used in expression vectors in mammalian cells include the HTLV-LTR promoter, early and late SV40 promoters, CMV promoters, the mouse metallothionein I (MMT) promoter, etc. A preferred example of an initiation codon is the methionine codon (ATG).

A polynucleotide encoding an amino acid sequence of the proteins

of the present invention may be obtained by, for example, partial or complete synthesis of nucleotides using a DNA synthesizer. Alternatively, it can be obtained from a human cDNA library by using a probe or primer set that is designed based on a nucleotide sequence 5 as shown in SEQ ID NO: 1 or SEQ ID NO: 3. The genomic DNA encoding the proteins of the present invention can also be prepared by treating genomic DNA according to a conventional method (e.g. digestion with restriction enzymes, dephosphorylation by bacterial alkaline phosphatase, phosphorylation by T4 polynucleotide Kinase, and 10 ligation with T4 DNA ligase). Furthermore, the genomic DNA thus obtained can be used to demonstrate the transcriptional initiation site of a gene of the present invention located on the genome. This allows one to specify expression-regulatory regions located upstream 15 of the gene. Regulatory regions, such as promoters and enhancers, which would control expression of a gene encoding a protein of the present invention, are useful as target regions for detecting aberrant expression of a protein of the present invention. Regulation of gene expression can be achieved using decoy nucleotide pharmaceuticals that target such regions.

20 Among proteins of the present invention, the active form protein has a lethal action at least to human cells. Therefore, in mammalian cells, it is desirable to express the active form protein in conjunction with a promoter capable of inducing the expression thereof. A temperature-sensitive promoter and drug-sensitive promoter are 25 known as such promoters. These promoters are activated only the specified culture conditions. Therefore, the expression can be induced at the stage in which cells are fully grown up.

30 Essential procedures of this invention such as DNA cloning, construction of each plasmids, transfection of host cells, culturing of transformants, recovery of proteins from cultures, and so forth can be carried out according to the methods well known to those skilled in the art or described in the references (Molecular Cloning 2<sup>nd</sup> edition, T. Maniatis et al., Cold Spring Harbor Laboratory (1989); DNA Cloning, D. M. Glover. IRL PRESS (1985), etc.).

35 The host cells of the present invention include cells used for functional analysis of the apoptosis-associated factor of the

present invention and those used for screening inhibitors or enhancers of the functions of the proteins. Introduction of a vector into host cells may be conducted using any of the methods including, for example, calcium phosphate precipitation, electroporation (Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 9.1-9.9), the lipofectamine method (Gibco-BRL), and microinjection. Preparation of the proteins of the present invention from transfectedants may be conducted using any of the isolation and purification methods well known to one skilled 10 in the art.

The present invention also provides a polynucleotide comprising at least 15 nucleotides, which is complementary to any of the polynucleotide sequences shown in SEQ ID NO: 1 or 3, or to a complementary strand thereof. As used herein, the term 15 "complementary strand" refers to one strand of a double-stranded polynucleotide that forms base pairs of A:T (A:U) and G:C with the other strand of the polynucleotide. Also, "complementary" is defined as not only sequences that completely match a continuous nucleotide region of at least 15 nucleotides, but also sequences 20 having a homology of at least 70%, preferably at least 80%, more preferably 90% or more, and most preferably 95% or more to that region. Sequence homology can be determined according to the algorithm as described in this description.

Such a polynucleotide can be used as a probe for isolating 25 and detecting the DNA or RNA encoding a protein of the invention, or as a primer for amplifying a polynucleotide. When used as a primer, the DNA usually comprises 15-100 bp, and preferably, 15-35 bp. When used as a probe, the DNA comprises the entire sequence of a DNA of the invention, or at least a part of it, and comprises at least 15 30 bp. When used as a primer, the 3'-region of the polynucleotide must be complementary, but the 5'-terminal may contain additional sequences, such as a restriction enzyme recognition site or a tag.

The polynucleotides of the present invention can be used for 35 testing or diagnosing aberrations in the proteins of the present invention. For example, the polynucleotides of the present invention can be used as probes or primers to test aberrations in

gene expression by Northern hybridization or RT-PCR. Alternatively, the polynucleotides of the present invention as primers can be used for polymerase chain reaction (PCR) to amplify the polynucleotides encoding the proteins of the present invention or the expression regulatory region thereof by genomic DNA-PCR or RT-PCR, and thus abnormalities of the sequence can be tested or diagnosed using RFLP analysis, SSCP, and sequencing. As used herein, the term "expression" includes transcription and/or translation. Expression analysis of the polynucleotides of the present invention 10 may allow the testing and diagnosing of gene expression at the transcriptional level. Gene expression at the translational level may be tested or diagnosed by using antibodies raised against the proteins of the present invention as described below.

Moreover, "a polynucleotide comprising at least 15 nucleotides, 15 which is complementary to any of the polynucleotide sequences as set forth in SEQ ID NO: 1 and 3, or to a complementary strand thereof" include antisense polynucleotides for inhibiting the expression of the proteins of the present invention. Antisense polynucleotides comprise at least 15 bp or more, preferably 100 bp or more, more 20 preferably 500 bp or more, and usually 3000 bp or less, preferably 2000 bp or less.

Such antisense polynucleotides are expected to be applied in gene therapy for diseases caused by aberrations (in function or expression) in the proteins of the present invention. Specifically, 25 apoptosis is an important step in damaging tissue caused by ischemic disease. Thus, if the expression of the present protein in the tissue in which a blood flow disorder occurred is inhibited, tissue damage accompanying ischemic disease can be reduced. An antisense polynucleotide can be prepared, for example, by utilizing the 30 phosphorothioate method based on the sequence information of a polynucleotide sequence shown in SEQ ID NO: 1 or 3 ("Physicochemical properties of phosphorothioate oligodeoxynucleotides." Stein (1988) Nucleic Acids Res. 16: 3209-3221).

A polynucleotide or antisense polynucleotide of the present 35 invention can be used in gene therapy, for example, by administrating it to a patient by utilizing the *in vivo* or *ex vivo* method using

vectors such as retrovirus vectors, adenovirus vectors, and adeno-associating virus vectors, or non-virus vectors such as liposomes.

The present invention also relates to an antibody capable of binding to a protein of the invention. The form of the antibody is not especially restricted; it includes polyclonal antibodies, monoclonal antibodies, or portions thereof, which are capable of binding to an antigen. It also includes antibodies of all classes. Furthermore, specialized antibodies such as humanized antibodies  
10 are also included.

If the antibody is a polyclonal antibody, it can be obtained according to the standard method by synthesizing a protein of this invention, or a partial peptide thereof, and immunizing rabbits with the protein or peptide (Current Protocols in Molecular Biology (1987) Ausubel et al. edit, John Wiley & Sons, Section 11.12-11.13). If the antibody is a monoclonal antibody, it can be obtained by immunizing mice with a protein of this invention, or a partial peptide thereof, and producing a hybridoma cell by fusing spleen cells and myeloma cells (Current Protocols in Molecular Biology (1987) Ausubel et al.  
15 edit, John Wiley & Sons, Section 11.4-11.11).

An antibody capable of binding to a protein of the present invention can be used for purifying a protein of the invention, and also for detecting and/or diagnosing aberrations in the expression and the structure of the protein. Specifically, proteins may be extracted from tissues, blood, or cells, and methods such as western blotting, immunoprecipitation, or ELISA can be used for the above purpose.

Furthermore, an antibody capable of binding to the proteins of the present invention may be utilized for treating diseases associated with the protein. If the antibody is used for treating patients, a human antibody or humanized antibody is desirable in terms of their low antigenicity. Human antibodies can be prepared by immunizing a mouse in which the immune system has been replaced with that of a human ("Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" Mendez M.J. et al. (1997) Nat. Genet. 15: 146-156, for a reference).

Humanized antibodies can be prepared by recombination of the hyper variable region of a monoclonal antibody (*Methods in Enzymology* (1991) 203: 99-121).

The present invention provides a method of screening for compounds regulating the activity of the proteins of the present invention. Since the proteins of the present invention causes cell death, compounds that suppress the activity of products of the gene may be useful as therapeutic agents or reagents for suppressing cell death. This screening method comprises the following steps of:

10 (1) contacting a candidate compound with cells expressing the protein of the present invention; and

(2) culturing the cells under the conditions for inducing apoptosis to select a candidate compound which suppresses or promotes apoptosis.

15 Cells expressing the protein of the present invention include those expressing the active or inactive form protein.

Since the expression of the active form protein in cells directly causes apoptosis, these cells per se are not expected to be useful for the effective screening. Thus, an expression plasmid in which the gene (of the active form protein) is linked downstream of a controllable promoter sequence can be used. A controllable promoter can include, for example, a metallothionein promoter or the like. Animal cells such as HEK293 are transformed with a plasmid which expresses the gene encoding the active form protein of the present invention under the control of a promoter as described above. The resulting transformant cause cell death under the conditions in which the promoter has been activated.

For example, the transformant is plated on 96-well multiplates, and then a subject candidate compound is added to each well, followed by the activation of the promoter. As a result, compounds to regulate the affect of the protein of the present invention can be selected by screening candidate compounds to suppress (or promote) apoptosis compared with a control. This method can be applied to any host cells in which cell death is induced in a similar system besides mammalian cells, regardless of eukaryotes or prokaryotes.

On the other hand, when the inactive form protein is to be

expressed, the production of the active form protein is induced by exposing host cells to the conditions for producing the active form protein. Specifically, if the inactive form protein is to be converted to the active form by the cleavage at the caspase recognition domain, the inactive form protein is expressed in host cells expressing the required caspase. Alternatively, for a transformant in which the caspase recognition domain is replaced with an amino acid sequence to be cleaved by a protease other than caspase, host cells producing the required protease may be used. Such protease 5 may be artificially transferred into cells, or an enzyme originally contained in the cells can be used. In either case, since the protease activity required for the production of the active form protein directly causes apoptosis, the production thereof is desirable to be controllable.

15 Screening of the present invention is carried out with apoptosis as an indicator. The method for detecting apoptosis is well known in the art. Specifically, apoptosis is detected in a usual method considering changes in cell form and DNA fragmentation as an indicator. Morphological changes of cells due to apoptosis can be observed as 20 changes in the stained image by the Giemsa stain or fluorescence stain. Alternatively, DNA fragmentation can be detected by TUNEL method (Gavriel, Y. et al., 1992, J Cell Biol. 119: 493-501). Furthermore, a method for detecting the early stage of apoptosis includes the Annexin V method (Vermes, I. et al., J. Immunol. Methods, 25 1995, Jul 17; 184 (1): 39-51), wherein the fluorescence label, Annexin V, bound to structurally altered cytoplasmic membranes is measured with a flow cytometer, and so forth.

Compounds selected by the screening method of the present invention include those which regulate the action of the protein 30 of the present invention by the following systems, wherein:

(1) compounds inhibit (or promote) the process whereby the protein of the present invention cleaved so as to be converted to active form thereof;

35 (2) compounds inhibit (or promote) the production of the protein of the present invention per se, and

(3) compounds inhibit (or promote) the cleavage of the inactive

form protein of the present invention by the activated caspase.

Increase of the gene expression product of the present invention in cells may easily promote cell death triggered by certain stimulus. Therefore, compounds that control the expression of the gene or that 5 promote cell death may be useful as the therapeutic agents or reagents for a variety of disorders (e.g., cerebral infarction, cancer, or etc.). The control of gene expression can be observed by the reporter assay. The present invention relates to a method for screening apoptosis-regulating substances according to a reporter assay in 10 which the expression-regulating region of the gene comprising the nucleotide sequence described in SEQ ID NO: 3 based on the present invention. A screening method of the present invention comprises the following steps of:

(1) contacting a candidate compound with a cell, wherein a 15 vector has been introduced into said cell, said vector comprising: an expression regulatory region of a gene of SEQ ID NO: 3, and, a reporter gene operably linked downstream of the expression regulatory region;

(2) measuring the activity of the reporter gene; and,

(3) selecting the candidate compound that increases or decreases the reporter activity measured when compared to the control.

A regulatory region that controls expression of a gene comprising a nucleotide sequence of SEQ ID NO: 3 may be cloned from chromosomal DNA by any method well known in the art. For example, 25 S1 mapping is well known as a method for specifying transcription initiation sites ("Isolation of Transcriptional Regulatory Region" and "Isolation and Purification of Transcription Factors" in Department Oncology, The Institute of Medical Science (ed.), "Current Protocols for Cellular Engineering", Cell Technology, Separate Volume 8, pp. 362-374, Shujunsha Co. Ltd., 1993). In general, screening of a human genomic library using a 15-100bp, preferably 30-50 bp fragment at the 5' terminus of the gene may allow cloning of the regulatory region DNA as a cloned gene comprising the expression regulatory region. The cloned DNA thus obtained often contains 10 30 kb or longer sequence of the 5'-untranslated region of the gene. Then, the 5'-terminal region of the cloned DNA is shortened or

fragmented by treating with, for example, an exonuclease. The minimal essential unit for maintaining the activity of the regulatory region can be found by evaluating the expression level or regulation of expression of the reporter gene using a sequence comprising a 5 shortened expression regulatory region (deletion study).

A computer program that predicts expression-regulatory regions of genes using Neural Network is widely known ([http://www.fruitfly.org/seq\\_tools/promoter.html](http://www.fruitfly.org/seq_tools/promoter.html), Reese, M.G., et al, "Large Scale Sequencing Specific Neural Networks for Promoter 10 and Splice Site Recognition" Biocomputing: Proceedings of the 1996 Pacific Symposium, edited by Lawrence Hunter and Terri E. Klein, World Scientific Publishing Co, Singapore, January 2-7, 1996). Alternatively, the minimal essential unit for maintaining the activity is predicted using a program such as the Promoter Scan program 15 that searches for a transcription factor binding sequence and predicts the expression regulatory region (<http://biosci.cbs.umn.edu/software/proscan/promoterscan.htm>, Prestridge, D.S. 1995, Prediction of Pol II Promoter Sequence using Transcription Factor Binding Sites. J. Mol. Biol. 249: 923-932). 20 The deletion study can be conducted, focusing on the core regions predicted.

An expression plasmid in which a reporter gene is operably linked downstream of the thus isolated gene for the regulatory region is constructed and introduced into an appropriate cell. As used herein, 25 the term "operably linked" means that the two elements are linked so that transcription of the reporter gene is initiated by activation of the above expression regulatory region. Any gene may be used as a reporter gene as long as it encodes a protein that allows one to observe an activation of the above regulatory region as an 30 expression of the gene. Particularly, genes such as luciferase,  $\beta$ -galactosidase, GFP (Green Fluorescent Protein) are typically used as reporter genes. Mammalian cells having a deletion in the corresponding gene, for example, can be used as cells for introducing the vector.

35 In the established cell line obtained as above, the promoter is activated under the conditions so as to cause cell death (apoptosis),

followed by the production of a signal by the reporter gene. Resulting cells are plated on 96-well multiplates to start culturing under the conditions to cause apoptosis. By adding target compounds for screening to each well, the compound that suppress or promote the production of expression product of the gene can be easily selected. As a method for selecting a compound, if GFP is used as the reporter gene, the fluorescence intensities between the presence and absence of the compound can be compared. Comparison refers to when the luminescence ration is two-folds or higher, or 1/2 or lower, preferably five-folds or higher, or 1/5 or lower, and more preferably 10-folds or higher, or 1/10 or lower. This method can be applied to not only animal cells, but also other cells, regardless of being of eukaryotic or prokaryotic origin, as long as they can express cell death in a similar system.

Candidate substances include, but are not limited to, for example, cell extracts, expression products of a gene library, synthetic low molecular weight compounds, synthetic peptides, native compounds, and so forth.

Compounds isolated by this screening are candidates for a compound that promotes or suppresses the activity or expression of a protein of the present invention (agonist or antagonist). They are also candidates as compounds that inhibit the interaction between the proteins of the present invention and certain molecules that interact with the proteins. These compounds may be possibly applied to the treatment or prevention of diseases related to the proteins of the present invention.

Furthermore, the present invention relates to a pharmaceutical use of substances that can be obtained by the screening method of the present invention. That is, the present invention relates to a use of pharmaceutical containing a compound obtainable by the above-described screening method as a principal component in the control of cell proliferation or cell death. Alternatively, the present invention relates to a therapeutic agent which is characterized by containing these compounds as the principal component, for disorders characterized by cell proliferation or cell death. In the present invention, disorders characterized by cell

proliferation or cell death mean those caused by the aberrant cell proliferation or cell death. Disorders caused by the aberrant cell proliferation may include, for example, cancers resulted from the proliferation of malignant tumor cells, etc. Alternatively, disorders caused by cell death may include the brain tissue damage caused by the cerebral ischemia. Compounds that inhibit the function or the production per se of the apoptosis-associated factor of the present invention can be used for the control of the following cell death:

- 10           (1) cell death due to ischemia;
- (2) cell death in chronic viral diseases and cell death in chronic diseases due to other pathogenic microorganisms;
- (3) inflammation due to the autoimmune reaction and associated cell death thereof; and,
- 15           (4) cryptogenic disorders (such as Alzheimer's disease) due to cell death and resulting degeneration.

These cell deaths are caused by, for example, the following diseases. Therefore, compounds selected by the screening method of the present invention can be also used for the treatment of the following disorders:

cerebrovascular disease dementia, multiple microcerebral infarction, cerebral thrombosis, cerebral infarction, and cerebral hemorrhage;

neurodegenerative disease (Alzheimer's disease, etc.);  
cardiac infarction and myocarditis;  
viral hepatitis, alcoholic hepatitis, and cirrhosis;  
insulin-dependent diabetes (due to the immunoreactive cell death of the pancreatic Langerhans' islet cell);  
ischemic enteritis;

30           cell death due to systemic or localized autoimmune disorders:  
systemic, generalized erythema, and dermatomyositis, rheumatoid arthritis; and

AIDS.

The proteins, nucleotides, antibodies of the present invention and the compounds isolated by the above screening mentioned are useful for regulating apoptosis. When used as pharmaceutical agents, they

themselves can be used as pharmaceutical agents, or they can be formulated for use by any known pharmaceutical method. For example, the compounds can be formulated by mixing with pharmacologically acceptable carriers or vehicles, specifically, sterilized water, 5 physiological saline, plant-oil, emulsifiers, suspending agents, and used. Methods well known to one skilled in the art may be used to administer a pharmaceutical agent to patients, for example as intra-arterial, intravenous, percutaneous injections, and so on. The dosage varies according to the body-weight and age of the patient, 10 and also the administration method, but one skilled in the art can suitably select an appropriate dosage. If the compound can be encoded by a polynucleotide, the polynucleotide can be inserted into a vector for gene therapy to perform the therapy. The dosage and method of administration vary according to the body-weight, age, and symptoms 15 of a patient, but one skilled in the art can select them suitably. Also, all publications cited herein are incorporated by reference.

Best Mode for Carrying out the Invention

The present invention will be explained in detail below with 20 reference to examples, but it is not to be construed as being limited thereto.

[Example 1] Construction of a cDNA library by the oligo-capping method

A cDNA library was prepared from the NT-2 neuron progenitor cells (purchased from Stratagene), which is a teratocarcinoma cell 25 derived from the fatal human testis and can differentiate into neurons by the treatment with retinoic acid. First, NT-2 cells were cultured without the induction by retinoic acid according to the manual supplied by the manufacturer, and then the cultured cells were harvested. mRNA was extracted by the method described in the 30 reference (J. Sambrook, E. F. Fritsch & T. Maniatis, Molecular Cloning Second edition, Cold Spring Harbor Laboratory Press 1989). Poly(A)<sup>+</sup> RNA was further purified from the mRNA using oligo-dT cellulose.

Poly(A)<sup>+</sup>RNA was used to construct a cDNA library by the 35 oligo-capping method (Maruyama M. and Sugano S. (1994) Gene 138: 171-174). Using the Oligo-cap linker (accaucgagu cggccuuguu ggccuacugg/SEQ ID NO: 5) and the Oligo-dT primer (gcggctgaag

acggcctatg tggccctttt tttttttt tt/SEQ ID NO: 6), BAP (Bacterial Alkaline Phosphatase) treatment, TAP (Tobacco Acid Phosphatase) treatment, RNA ligation, the first strand cDNA synthesis, and removal of RNA were performed as described in the reference (Suzuki and Kanno 5 (1996) Protein Nucleic acid and Enzyme. 41: 197-201; Suzuki Y. et al. (1997) Gene 200: 149-156). Next, 5'- and 3'-PCR primers ((agcatcgagt cggcctgtt g/SEQ ID NO: 7) and (gcggctgaag acggcctatg t/SEQ ID NO: 8) respectively) were used to perform PCR (polymerase chain reaction) to convert the first-strand cDNA into double-stranded 10 cDNA, which was then digested with SfiI. Then, the DraIII-digested vector pME18SFL3 was used for cloning the cDNA with correct orientation, and cDNA libraries were obtained. The clones having an insert cDNA of 1 kb length or shorter were removed for the plasmid DNAs of the clones thus obtained. Then, the nucleotide sequence 15 of the 5'- and 3'- ends of the cDNA clones was analyzed using DNA sequencing reagents (Dye Terminator Cycle Sequencing FS Ready Reaction Kit, dRhodamine Terminator Cycle Sequencing FS Ready Reaction Kit, or BigDye Terminator Cycle Sequencing FS Ready Reaction Kit, from by PE Biosystems), performing sequencing reactions 20 according to the instructions, and analyzing with a DNA sequencer (ABI PRISM 377, PE Biosystems).

The fullness ratio of the 5'-end sequence of the cDNA clones in the libraries constructed by the oligo-capping method was determined as follows. For all the clones in which the 5'-end sequence 25 was identical to that of any known human mRNA in the public database, the clones were judged to be "complete/full length", if they had longer 5'-end sequences than the known human mRNA, or, even if the 5'-end sequence was shorter, if they contained a translational initiation codon. A clone that did not contain a translational initiation codon was judged to be "incomplete/not full-length". The fullness ratio ((the number of complete clones)/(the number of complete clones) + (the number of incomplete clones)) of the 5'-end 30 of the cDNA clones was determined by comparing with the known human mRNA. As a result, the fullness ratio of the 5' end sequence of the cDNA clone in this library (NT2RML) was determined to be 69%, indicating the extreme high ratio thereof.

Next, using a protein localization-predicting program "PSORT", developed by Nakai and Kanehisa, the presence of sequences estimated to be signal peptides characteristic of the amino termini of many secretory proteins was analyzed for all the deduced amino acid sequences initiating from each ATG codon in the 5'-end sequence of clones of the library prepared by the oligo-capping method. Thus, clones estimated to comprise signal sequences (most likely to be secretory proteins or membrane proteins) were specifically selected from the clones of the library prepared by the oligo-capping method.

Furthermore the complete cDNA sequence and the predicted amino acid sequence of the clones thus selected were determined. The final nucleotide sequences were determined by combining the following three methods, and overlapping the nucleotide sequences determined by each method.

(1) Long read sequencing from both ends of the cDNA inserts using a Licor DNA sequencer (Sequence reactions were performed according to the manual of the Licor sequencer (Aloka), and DNA sequence was determined using the sequencer.)

(2) Nested sequencing by the Primer Island method which utilizes the in vitro integration reaction of AT2 transposon (Devine S.E., and Boeke J.D. (1994) Nucleic Acids Res. 22: 3765-3772) (Clones were obtained using a kit from PE Biosystems, and sequence reactions were performed using the DNA sequencing reagents from the same company, according to the manufacturer's instructions, and DNA sequence was determined using an ABI PRISM 377 sequencer).

(3) Primer walking by the dideoxy terminator method using custom synthesized DNA primers (Sequencing reactions were performed using the DNA sequencing reagents from PE Biosystems and custom synthesized DNA primers according to the manufacturer's instructions. DNA sequence was determined using an ABI PRISM 377 sequencer).

Obtained sequences were subjected to analysis by ATGpr [A. A. Salamov, T. NISHIKAWA, M. B. Swindells, Bioinformatics, 14: 384-390 (1998); <http://www.hri.co.jp/atgpr/>] and PSORT, and also to BLAST search of GenBank and SwissProt. PSC0004 is a "cloned derived from a human cDNA library prepared by the oligo-capping method with high fullness ratio, predicted to be a full-length cDNA clone by using

the programs such as ATGpr, and predicted to be a secretory protein or membrane protein having the signal sequence at the N-terminus by using PSORT". The above results are demonstrated below:

Name of clone: PSEC0004

5 cDNA size: 1883 bp: C-NT2RM1000558

The number of constitutive amino acid in a putative amino acid sequence: 326

The number of ATG counted from the N-terminus: 1

Maximum ATGpr1 value: 0.94

10 Annotation: 532/852 (62%) similarity to human death effector domain-containing testicular molecule mRNA

[Example 2] Functional prediction by homology analyses

Some genes associated with apoptosis have been reported to share the Death Effector Domain (DED) among them (Chinnaiyan, A. M. et al., 1995, Cell 81: 505-512; Muzio, M. et al., 1996, Cell 85: 817-827; Fernandes-Alnemri, 1996, Proc. Natl. Acad. Sci. USA 93: 7464-7469). For example, similarly to FADD and Caspase-8, which play an important role in the apoptosis signaling by CD95 (Fas), DEDD has been reported to be a novel molecule comprising DED (Alexander H. Stegh et al., 1998, The EMBO Journal Vol. 17 No. 20, 5974-5986; Peter, M.E. et.al., 1995, Cell Death Differ., 2, 163-171). Therefore, using the N-terminal 76 amino acid residues on DEDD (LYSLHRMF DIVGTHLTHRDVRVLSFLFLVDVIDDHHERGLIRNGRDFLLALERQGRCDESNFR QVLQLLRIITRHDLL/ SEQ ID NO: 9 (DEDD: 23-99)) as query, homology analysis (Blast 2) was performed for the amino acid sequence encoded by the above-described full-length cDNA clone. As a result, the amino acid sequence encoded by NT2RM1000558 showed about 43% homology.

Similarly to DEDD, some genes associated with apoptosis have been reported to encode comprising a specific amino acid sequence (DEXD) cleaved by caspase, which is considered to be an effector protein for apoptosis. Therefore, using this sequence (DEXD) as query, homology analysis (Blast 2) was performed for the amino acid sequence encoded by the above-described full-length cDNA clone. As a result, the DEAD sequence was also detected in proximity to the C-terminus of the amino acid sequence encoded by NT2RM1000558.

Results described above have predicted that the NT2RM1000558 clone is an apoptosis-associated gene. Furthermore, comparison of sequences between NT2RM1000558 and DEDD revealed that the former comprised a sequence having a high homology to the NLS domain, which had been found in DEDD, indicating that NT2RM1000558 retained an apoptosis-associated function.

5 [Example 4] Expression in various human tissue distribution

10 Expression of NT2RM1000558, which had been predicted to have the apoptosis-associated function, in various human tissues was examined. Using the primer 1 (TCAGTGTGGATGAGGCTGACT/ SEQ ID NO: 10 (NT2RM1000558: at positions 1013-1033)) and primer 2 (TGCACCTGTGACAGTGCAGA/ SEQ ID NO: 11 (NT2RM1000558: at positions 1399-1380)), PCR was performed (for 30 cycles) with the Multiple 15 Tissue cDNA Panels (Clontech) (CODE K1420-1, K1426-1) as a template DNA according to the manual provided by the manufacturer. After the reaction, the mixture was electrophoresed on agarose gel, and expression levels of NT2RM1000558 in respective tissues were confirmed from the results of electrophoresis.

20 As a result, no tissue specificity was observed in the expression of NT2RM1000558 was confirmed in many tissues (including brain, heart, kidney, liver, lung, pancreas, placenta, bone marrow, lymph node, leukocytes, spleen, thymus and tonsil).

25 [Example 5] Functional analysis of NT2RM1000558

In the following expression analysis, the pcDNA3.1 vector (Invitrogen) was used for all cDNA constructs. The vector strongly induces the expression of foreign genes in mammalian cells under the control of CMV promoter.

30 The NT2RM1000558 gene inserted into the restriction enzyme Dra III site of pME18SFL3 was excised by digestion with restriction enzymes EcoRI and NotI. On the other hand, pcDNA3.1 (Invitrogen), an expression vector, was similarly digested with restriction enzymes EcoRI and NotI, and ligated with the purified gene fragment described 35 above. The resulting pcDNA3.1 vector inserted with the entire NT2RM1000558 gene was used as intact protein expression vector.

Next, a vector for expressing the active form protein was constructed as follows. First, with the NT2RM1000558 gene inserted into the restriction enzyme Dra III site of pME18SFL3 as a template, PCR was performed using the Advantage GC rich PCR kit (Clontech).  
5 The sense primer, 90-GGTTCTGAGCTTGTCC (SEQ ID NO: 12), which is used in PCR, comprises the nucleotide sequence corresponding to that of the 5'-noncoding region of the NT2RM1000558 gene. On the other hand, the antisense primer, TCAGTCAGCCTCATCCACACTGA-1013 (SEQ ID NO: 13), comprises the nucleotide sequence encoding the amino acid  
10 sequence VSVDEAD portion of the protein, added with the nucleotide sequence corresponding to a stop codon just downstream of it. After PCR was completed, the PCR product (active form) was subcloned into the pT7Blue-2T (Novagen), which is a TA-cloning vector. The active form NT2RM1000558 gene inserted into the pT7Blue-2T was sequenced  
15 with the SP6 primer and M13 primer using the BigDye terminator Cycle sequence kit (PE Biosystems) and PE310 Genetic Analyzer (PE Biosystems), it was confirmed that the nucleotide sequence of the active form NT2RM1000558 gene had no mutations due to PCR.

Furthermore, the active form NT2RM1000558 gene inserted in  
20 pT7Blue-2T was digested at the restriction enzymes EcoRI and XhoI sites on pT7Blue-2T with these restriction enzymes, followed by excising. Then, the expression vector pcDNA3.1 was similarly digested with the restriction enzymes EcoRI and XhoI, and ligated with the purified gene fragment described above. The resulting  
25 pcDNA3.1 vector inserted with the active form NT2RM1000558 gene was used as the active form protein expression vector.

HEK293T cells were plated at  $2 \times 10^5$  cells per well on 6-well plates, and cultured overnight. To the Lipofectamine 2000 solution (Gibco BRL) (10  $\mu$ l), the Opti-MEM solution (250  $\mu$ l) was added, stirred, and allowed to stand for 5 minutes at room temperature. The plasmid DNA (either the intact or active form expression vector) (4  $\mu$ g) and Opti-MEM solution (250  $\mu$ l) are mixed together, added to the resulting mixture described above, and allowed to stand for further 20 minutes at room temperature. By adding the resulting Lipofectamine 30 2000-plasmid DNA mixture to the above-described cultured cells, followed by culturing for 30 hours, the cells were introduced with

either the intact form gene or active form gene.

After removing the culture medium from the cells, PBS-EDTA solution (2 ml) was added to the cells and then suspended with detached cells from the plates by pipetting. The resulting mixture was 5 centrifuged at 400x g for 5 minutes to remove the supernatant PBS. The cells were further suspended in added PBS (1 ml), and centrifuged at 400x g for 5 minutes to remove the supernatant PBS.

Subsequently, the cells were suspended in 1% glutaraldehyde solution (100 µl) added, and fixed by allowed to stand for 30 minutes 10 at room temperature. Then, the cells were centrifuged at 400x g for 5 minutes to remove the supernatant fixative. The cells were further suspended in PBS (1 ml) added, and centrifuged at 400x g for 5 minutes to remove the supernatant PBS.

The cells were suspended in PBS (20 µl) added, and further 15 mixed with 1 mM HOECHST 33258 solution (SIGMA) (fluorescence dye) (5 µl). With a drop of the cell suspension overlaid with a cover glass on a slide glass, the nuclear form (nuclear fragmentation) was observed under a fluorescence microscope.

Nuclear fragmentation due to apoptosis was not observed in 20 the cells into which the full-length sequence of NT2RM1000558 gene (encoding 326 amino acid residues) had been introduced by the above method, but was observed in the cells into which an activated form NT2RM1000558 gene (encoding 303 amino acid residues), which lacked the region downstream from the DEAD portion in the NT2RM1000558 gene, 25 had been introduced. As a control, nuclear fragmentation due to apoptosis was also observed in cells into which the Caspase-3 gene had been introduced.

Considering the substrate specificity of the caspase family to the cleavage recognition sequence, it is assumed that the DEAD 30 sequence, the cleavage sequence recognized by the activated caspase in the NT2RM1000558 gene is a molecule, which is activated by the cleavage with Caspase-3, Caspase-6, and Caspase-7, playing the ultimate role in the apoptosis execution similarly to the poly (ADP-ribose) polymerase (PARP) and DNA fragmentation factor.

35 A protein synthesized from the NT2RM1000558 gene via *in vitro* transcription/translation system indicated a 36 kd band in SDS-PAGE.

Thus, it was confirmed that, in this gene, the actual protein translation initiates from the initiator methionine in the reading frame as predicted.

5 Industrial Applicability

The present invention has provided a novel apoptosis-associated factor, which comprises the recognition site for the group 2 caspase constituting downstream of the apoptosis execution cascade. Therefore, the apoptosis-associated factor of the present invention may be an important protein involved in the final stage of apoptosis. Actually, symptoms of typical apoptosis have become to be observed in cells, in which active form molecules of the apoptosis-associated factor of the present invention have been overexpressed. Therefore, compounds that control the action of the apoptosis-associated factor of the present invention can be screened using apoptosis as an indicator. Compounds that may be obtained by the screening method of the present invention are useful as drugs to control the cell proliferation or cell death.

For example, compounds that suppress the action of the apoptosis-associated factor of the present invention can be used as drugs to prevent the progression of apoptosis. Since the apoptosis-associated factor of the present invention functions at the final stage of apoptosis execution cascade, compounds that interfere with the action may effectively suppress apoptosis. The apoptosis-associated factor of the present invention is widely distributed over respective human tissues, and is predicted to play a critical role for a variety of the above-described disorders with impairments spread by apoptosis. The apoptosis-associated factor of the present invention was isolated from neurocytes in particular. The control of apoptosis induced with cerebral ischemia is important objects in the prevention and treatment of injuries of brain tissues. The apoptosis-associated factor of the present invention is important as a target molecule for the prevention and treatment of damages of brain tissues.

On the contrary, compounds that enhance the action of apoptosis-associated factor of the present invention or stimulate

the production thereof are useful as drugs to promote cell death. The apoptosis-associated factor of the present invention strongly induces apoptosis. Therefore, the apoptosis-associated factor per se of the present invention or compounds promoting the production 5 thereof can be used as drugs to suppress the cell proliferation, for example, in cell proliferative disorders such as cancer.

Although apoptosis can be induced by a variety of causes, drugs which act at the final stage of the execution cascade thereof may control apoptosis regardless of its causes. Therefore, compounds 10 capable of controlling actions of the apoptosis-associated factor of the present invention can be expected to achieve the control of apoptosis in a broad range of disorders.

## CLAIMS

1. A polynucleotide encoding a protein having apoptosis-inducing activity, said polynucleotide selected from the group consisting of the following (a) to (d):

5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1;

(b) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 2;

10 (c) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 2 in which one or more amino acids are substituted, deleted, inserted, and/or added; and

15 (d) a polynucleotide hybridizing under stringent conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1.

2. The polynucleotide of claim 1, said polynucleotide having 60% or more homology to the nucleotide sequence of SEQ ID NO: 1.

3. A polynucleotide encoding a precursor of a protein having apoptosis-inducing activity, said polynucleotide selected from the group consisting of the following (e) to (h):

20 (e) a polynucleotide comprising a protein coding region of the nucleotide sequence of SEQ ID NO: 3;

(f) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 4;

25 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 4 in which one or more amino acids are substituted, deleted, inserted, and/or added; and

(h) a polynucleotide hybridizing under stringent conditions with a polypeptide comprising the nucleotide sequence of SEQ ID NO:

30 3.

4. The polynucleotide of claim 3, said polynucleotide having 60% or more homology to the nucleotide sequence of SEQ ID NO: 3.

5. A polynucleotide encoding a partial peptide of a protein encoded by the polynucleotide of claims 1 or 3.

35 6. A polynucleotide encoding molecular-evolutionarily the same gene as a gene comprising the nucleotide sequence of SEQ ID NO: 3.

7. A polynucleotide encoding a protein that comprises the amino acid sequence of SEQ ID NO: 4 in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a character dominant negative to that of a protein comprising the amino acid sequence of SEQ ID NO: 4.

5       8. The polynucleotide of claim 7, said polynucleotide encoding the amino acid sequence of SEQ ID NO: 4 in which the amino acid sequence at position 300 to 303 has been modified to a caspase-resistant amino acid sequence.

10      9. A protein encoded by the polynucleotide according to any one of claim 1, claim 3, claim 5, claim 6, and claim 7.

10      10. A vector comprising the polynucleotide according to any one of claim 1, claim 3, claim 5, claim 6, and claim 7.

15      11. A transformant retaining the polynucleotide according to any one of claim 1, claim 3, claim 5, claim 6, and claim 7, or the vector of claim 10.

15      12. A method for producing the protein of claim 9, said method comprising the steps of:

- (1) culturing the transformant of claim 11; and
- 20     (2) recovering an expression product.

13. A polynucleotide comprising a polynucleotide complementary to the polynucleotide according to any one of claim 1, claim 3, claim 5, claim 6, and claim 7 or a complementary strand thereof, said polynucleotide being at least 15 bases long.

25      14. An antibody against the protein of claim 9.

15. An immunological assay method comprising a step of observing an immunological reaction between the protein of claim 9 and the antibody of claim 14.

30      16. A method for screening a substance regulating apoptosis, said method comprising the following steps of:

12      (1) contacting, with a candidate substance, cells expressing a protein encoded by the polynucleotide of claim 1 or claim 3; and  
17      (2) culturing said cells under conditions inducing apoptosis to select a candidate substance that suppresses or promotes apoptosis.

35      17. A method for screening a substance regulating apoptosis, said method comprising the following steps of:

(1) contacting, with a candidate substance, cells into which a vector comprising an expression control region for a gene comprising the nucleotide sequence of SEQ ID NO: 3 and a reporter gene operably linked downstream thereof has been introduced;

5 (2) measuring activity of said reporter gene; and

(3) selecting a candidate substance that increases or decreases the reporter gene activity in the step (2) compared with a control.

18. Use of a compound that can be obtained by the method of claim 16 or claim 17, in regulation of cell proliferation or cell death.

10 19. A therapeutic agent for disorders characterized by cell proliferation or cell death, said agent comprising, as a principal ingredient, a compound that can be obtained by the method of claim 16 or claim 17.

## ABSTRACT

A novel apoptosis-associated factor is provided. The apoptosis-associated factor of the present invention is a novel protein having DED, caspase family-cleavage domain, etc. This protein induces apoptosis in cells. Thus, a compound which is useful in regulating apoptosis can be screened by using this protein as a target. Moreover, the protein per se is useful in regulating diseases with cell proliferation.

## **Declaration and Power of Attorney For Patent Application**



特許出願宣言書及び委任状

## **Japanese Language Declaration**

## 日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、郵便の宛先、国籍は下記の私の氏名の後に記載された通りです。

My residence, mailing address and citizenship are as stated next to my name.

下記の名称の発明に關て請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

APOPTOSIS-ASSOCIATED FACTOR

上記発明の明細書は、

the specification of which

□ 本書に添付されています。

is attached hereto.

□ 月 日に提出され、米国出願番号または特

was filed on July 6, 2000

### 許協定各約國際出版番号を

as United States Application Number or PCT International Application Number

(該当する場合) に該当されません。

PCT/JP00/04516 and was amended on  
(if applicable)

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

## Japanese Language Declaration (日本語宣言書)

私は、米国法典第 35 編 119 条(a) – (d)項又は 365 条 (b) 項に基づき下記の、米国以外の国の少なくとも一ヵ国を指定している特許協力条約 365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)  
外国での先行出願

| 11-194179        | Japan             |
|------------------|-------------------|
| (Number)<br>(番号) | (Country)<br>(国名) |

私は、第 35 編米国法典 119 条 (e) 項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

| (Application No.)<br>(出願番号) | (Filing Date)<br>(出願日) |
|-----------------------------|------------------------|
|-----------------------------|------------------------|

私は、下記の米国法典第 35 編 120 条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約 365 条 (c) に基づく権利をここに主張します。また、

本出願の各請求範囲の内容が米国法典第 35 編 112 条第 1 項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国提出日までの期間中に入手された、連邦規則法典第 37 編 1 条 56 項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

| PCT/JP00/04516              | 6 July 2000            |
|-----------------------------|------------------------|
| (Application No.)<br>(出願番号) | (Filing Date)<br>(出願日) |

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第 18 編第 1001 条に基づき、罰金または拘禁、もしくはその両方ににより処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, § 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Claimed  
優先権主張

|                                   |   |                                    |
|-----------------------------------|---|------------------------------------|
| 8 July 1999                       | <input checked="" type="checkbox"/> Yes<br>はい | <input type="checkbox"/> No<br>いいえ |
| (Day/Month/Year Filed)<br>(出願年月日) |   |                                    |

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

|                             |                        |
|-----------------------------|------------------------|
| 60/159,586                  | 18 October 1999        |
| (Application No.)<br>(出願番号) | (Filing Date)<br>(出願日) |

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

|   |
|---|
| Pending   |
| (Status: Patented, Pending, Abandoned)<br>(現況: 特許許可済、係属中、放棄済) |

|   |
|---|
| (Status: Patented, Pending, Abandoned)<br>(現況: 特許許可済、係属中、放棄済) |
|---|

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**Japanese Language Declaration**  
**(日本語宣言書)**

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。  
 (弁護士、または代理人の指名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)



**022850**

書類送付先

Send Correspondence to:



**022850**

直接電話連絡先：(名前及び電話番号)

Direct Telephone calls to: (name and telephone number)

**(703) 413-3000**

|                     |  |   |
|---------------------|--|---|
| 単独発明者または第一の共同発明者の氏名 |  | Full name of first inventor<br><u>Toshio OTA</u>                    |
| 発明者の署名              | 日付   | Inventor's signature<br><u>Toshio OTA</u> Date <u>June 10, 2002</u> |
| 住所                  | Residence<br>c/o Kyowa Hakko Kogyo Co., Ltd., Tokyo Research Laboratories, 3-6-6, Asahi-machi, Machida-shi, TOKYO 194-8533, JAPAN <u>JPX</u> |   |
| 国籍                  | Citizenship<br>Japan   |   |
| 郵便の宛先               | Mailing Address<br>same as above   |   |

|             |   |  |
|-------------|---|--|
| 第二の共同発明者の氏名 |   | Full name of second joint inventor, if any<br><u>Takao ISOGAI</u>            |
| 第二の共同発明者の署名 | 日付  | Second Inventor's signature<br><u>Takao ISOGAI</u> Date <u>June 10, 2002</u> |
| 住所          | Residence<br>511-12, Omuro, Ami-machi, Inashiki-gun, IBARAKI 300-0303, JAPAN <u>JPX</u> |  |
| 国籍          | Citizenship<br>Japan  |  |
| 郵便の宛先       | Mailing Address<br>same as above  |  |

**Japanese Language Declaration**  
**(日本語宣言書)**

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。  
 (弁護士、または代理人の指名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)



**022850**

書類送付先

Send Correspondence to:



**022850**

直接電話連絡先：(名前及び電話番号)

Direct Telephone calls to: (name and telephone number)

**(703) 413-3000**

|                     |   |                           |
|---------------------|---|---------------------------|
| 単独発明者または第一の共同発明者の氏名 | Full name of first inventor<br>Toshio OTA   |                           |
| 発明者の署名              | 日付  | Inventor's signature Date |
| 住所                  | Residence<br>c/o Kyowa Hakko Kogyo Co., Ltd., Tokyo<br>Research Laboratories, 3-6-6, Asahi-machi,<br>Machida-shi, TOKYO 194-8533, JAPAN |                           |
| 国籍                  | Citizenship<br>Japan  |                           |
| 郵便の宛先               | Mailing Address<br>same as above  |                           |

|             |   |                                  |
|-------------|---|----------------------------------|
| 第二の共同発明者の氏名 | Full name of second joint inventor, If any<br>Takao ISOGAI                      |                                  |
| 第二の共同発明者の署名 | 日付  | Second inventor's signature Date |
| 住所          | Residence<br>511-12, Omuro, Ami-machi, Inashiki-gun,<br>IBARAKI 300-0303, JAPAN |                                  |
| 国籍          | Citizenship<br>Japan  |                                  |
| 郵便の宛先       | Mailing Address<br>same as above  |                                  |

**Japanese Language Declaration**  
**(日本語宣言書)**

|             |   |   |
|-------------|---|---|
| 第三の共同発明者の氏名 | Full name of third joint inventor, if any<br><u>Tetsuo NISHIKAWA</u>            |   |
| 第三の共同発明者の署名 | 日付  | Third inventor's signature Date<br><i>Tetsuo Nishikawa</i> <i>June 11, 2002</i> |
| 住所          | Residence<br>27-3-403, Hikawa-cho, Itabashi-ku, <u>TOKYO</u><br>173-0013, JAPAN |   |
| 住所          | Citizenship<br>Japan <span style="float: right;">JPX</span>                     |   |
| 郵便の宛先       | Mailing Address<br>same as above  |   |

|             |   |   |
|-------------|---|---|
| 第四の共同発明者の氏名 | Full name of fourth joint inventor, if any<br><u>Yuri HIO</u>                 |   |
| 第四の共同発明者の署名 | 日付  | Fourth inventor's signature Date<br><i>Yuri Hio</i> |
| 住所          | Residence<br>4508-19-201, Yana, Kisarazu-shi, <u>CHIBA</u><br>292-0812, JAPAN |   |
| 住所          | Citizenship<br>Japan <span style="float: right;">JPX</span>                   |   |
| 郵便の宛先       | Mailing Address<br>same as above  |   |

|             |   |   |
|-------------|---|---|
| 第五の共同発明者の氏名 | Full name of fifth joint inventor, if any<br><u>Sousuke MIYOSHI</u>   |   |
| 第五の共同発明者の署名 | 日付  | Fifth inventor's signature Date<br><i>Sousuke Miyoshi</i> |
| 住所          | Residence<br>3-19-1-2-306, Azuma, Tsukuba-shi, <u>IBARAKI</u><br>305-0031, JAPAN <span style="float: right;">JPX</span> |   |
| 住所          | Citizenship<br>Japan  |   |
| 郵便の宛先       | Mailing Address<br>same as above  |   |

|             |   |  |
|-------------|---|--|
| 第六の共同発明者の氏名 | Full name of sixth joint inventor, if any<br><u>Susumu SATOH</u>  |  |
| 第六の共同発明者の署名 | 日付  | Sixth inventor's signature Date<br><i>Susumu Satoh</i> |
| 住所          | Residence<br>6-19-11, Kinunodai, Yawara-mura, Tsukuba-gun,<br><u>IBARAKI</u> 300-2436, JAPAN <span style="float: right;">JPX</span> |  |
| 住所          | Citizenship<br>Japan  |  |
| 郵便の宛先       | Mailing Address<br>same as above  |  |

**Japanese Language Declaration**  
**(日本語宣言書)**

|             |   |  |                             |
|-------------|---|--|-----------------------------|
| 第三の共同発明者の氏名 | Full name of third joint inventor, if any<br>Tetsuo NISHIKAWA                         |  |                             |
| 第三の共同発明者の署名 | 日付  | Third inventor's signature                     | Date                        |
| 住所          | Residence<br>27-3-403, Hikawa-cho, Itabashi-ku, TOKYO<br>173-0013, JAPAN              |  |                             |
| 住所          | Citizenship<br>Japan  |  |                             |
| 郵便の宛先       | Mailing Address<br>same as above  |  |                             |
|             |   |  |                             |
| 第四の共同発明者の氏名 | Full name of fourth joint inventor, if any<br>Yuri HIO                                |  |                             |
| 第四の共同発明者の署名 | 日付  | Fourth inventor's signature<br><i>Yuri Hio</i> | Date<br><i>May 30, 2002</i> |
| 住所          | Residence<br>4508-19-201, Yana, Kisarazu-shi, CHIBA<br>292-0812, JAPAN                |  |                             |
| 住所          | Citizenship<br>Japan  |  |                             |
| 郵便の宛先       | Mailing Address<br>same as above  |  |                             |
|             |   |  |                             |
| 第五の共同発明者の氏名 | Full name of fifth joint inventor, if any<br>Sousuke MIYOSHI                          |  |                             |
| 第五の共同発明者の署名 | 日付  | Fifth inventor's signature                     | Date                        |
| 住所          | Residence<br>3-19-1-2-306, Azuma, Tsukuba-shi, IBARAKI<br>305-0031, JAPAN             |  |                             |
| 住所          | Citizenship<br>Japan  |  |                             |
| 郵便の宛先       | Mailing Address<br>same as above  |  |                             |
|             |   |  |                             |
| 第六の共同発明者の氏名 | Full name of sixth joint inventor, if any<br>Susumu SATOH                             |  |                             |
| 第六の共同発明者の署名 | 日付  | Sixth inventor's signature                     | Date                        |
| 住所          | Residence<br>6-19-11, Kinunodai, Yawara-mura, Tsukuba-gun,<br>IBARAKI 300-2436, JAPAN |  |                             |
| 住所          | Citizenship<br>Japan  |  |                             |
| 郵便の宛先       | Mailing Address<br>same as above  |  |                             |

**Japanese Language Declaration**  
**(日本語宣言書)**

|             |   |  |
|-------------|---|--|
| 第三の共同発明者の氏名 | Full name of third joint inventor, If any<br>Tetsuo NISHIKAWA                         |  |
| 第三の共同発明者の署名 | 日付  | Third Inventor's signature Date  |
| 住所          | Residence<br>27-3-403, Hikawa-cho, Itabashi-ku, TOKYO<br>173-0013, JAPAN              |  |
| 住所          | Citizenship<br>Japan  |  |
| 郵便の宛先       | Mailing Address<br>same as above  |  |
| 第四の共同発明者の氏名 | Full name of fourth joint inventor, If any<br>Yuri HIO                                |  |
| 第四の共同発明者の署名 | 日付  | Fourth inventor's signature Date   |
| 住所          | Residence<br>4508-19-201, Yana, Kisarazu-shi, CHIBA<br>292-0812, JAPAN                |  |
| 住所          | Citizenship<br>Japan  |  |
| 郵便の宛先       | Mailing Address<br>same as above  |  |
| 第五の共同発明者の氏名 | Full name of fifth joint inventor, If any<br>Sousuke MIYOSHI                          |  |
| 第五の共同発明者の署名 | 日付  | Fifth inventor's signature Date<br><i>Sousuke Miyoshi</i> <i>April. 12. 2002</i> |
| 住所          | Residence<br>3-19-1-2-306, Azuma, Tsukuba-shi, IBARAKI<br>305-0031, JAPAN             |  |
| 住所          | Citizenship<br>Japan  |  |
| 郵便の宛先       | Mailing Address<br>same as above  |  |
| 第六の共同発明者の氏名 | Full name of sixth joint inventor, If any<br>Susumu SATOH                             |  |
| 第六の共同発明者の署名 | 日付  | Sixth inventor's signature Date<br><i>Susumu Satoh</i> <i>April. 12. 2002</i>    |
| 住所          | Residence<br>6-19-11, Kinunodai, Yawara-mura, Tsukuba-gun,<br>IBARAKI 300-2436, JAPAN |  |
| 住所          | Citizenship<br>Japan  |  |
| 郵便の宛先       | Mailing Address<br>same as above  |  |

SEQUENCE LISTING

<110> Helix Research Institute.

<120> APOPTOSIS-ASSOCIATED FACTOR

<130> H1-106PCT1

<140>

<141>

<150> JP 1999-194179

<151> 1999-07-08

<150> US 60/159586

<151> 2000-10-18

<160> 13

<170> PatentIn Ver. 2.0

<210> 1

<211> 909

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(909)

<400> 1

atg gcg cta tcc ggg tcg acc ccg gcc ccg tgc tgg gag gag gat gag 48  
Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp Glu  
1 5 10 15

tgc ctg gac tac tac ggg atg ctg tcg ctt cac cgt atg ttc gag gtg 96  
Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu Val  
20 25 30

gtg ggc ggg caa ctg acc gag tgc gag ctg gag ctc ctg gcc ttt ctg 144  
Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Ala Phe Leu  
35 40 45

ctg gat gag gct cct ggc gcc ggc gga ggc tta gcc cgg gcc cgc agc 192  
Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg Ser  
50 55 60

ggc cta gag ctc ctg ctg gag cgc cgc ggg cag tgc ggc gag 240

|   |     |     |     |
|---|-----|-----|-----|
| Gly Leu Glu Leu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly Glu |     |     |     |
| 65  | 70  | 75  | 80  |
| agc aac ctg cgg ctg ctg ggg caa ctc ctg cgc gtg ctg gcc cgc cac |     |     | 288 |
| Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg His |     |     |     |
| 85  | 90  | 95  |     |
| gac ctg ctg cgg cac ctg gcg cgc aag cgg cgc cgg cca gtg tct cca |     |     | 336 |
| Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser Pro |     |     |     |
| 100   | 105 | 110 |     |
| gaa cgc tat agc tat ggc acc tcc agc tct tca aag agg aca gag ggt |     |     | 384 |
| Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Lys Arg Thr Glu Gly     |     |     |     |
| 115   | 120 | 125 |     |
| agc tgc cgt cgc cgt cgg cag tca agc agt tct gca aat tct cag cag |     |     | 432 |
| Ser Cys Arg Arg Arg Arg Gln Ser Ser Ser Ala Asn Ser Gln Gln     |     |     |     |
| 130   | 135 | 140 |     |
| ggt cag tgg gag aca ggc tcc ccc cca acc aag cgg cag cgg cgg agt |     |     | 480 |
| Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg Ser |     |     |     |
| 145   | 150 | 155 | 160 |
| cgg ggc cgg ccc agt ggt ggt gcc aga cgg cgg cgg aga ggg gcc cca |     |     | 528 |
| Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala Pro |     |     |     |
| 165   | 170 | 175 |     |
| gcc gca ccc cag cag cag tca gag ccc gcc aga cct tcc tct gaa ggc |     |     | 576 |
| Ala Ala Pro Gln Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu Gly |     |     |     |
| 180   | 185 | 190 |     |
| aaa gtg acc tgt gac atc cgg ctc cgg gtt cga gca gag tac tgc gag |     |     | 624 |
| Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys Glu |     |     |     |
| 195   | 200 | 205 |     |
| cat ggg cca gcc ttg gag cag ggc gtg gca tcc cgg cgg ccc cag gcg |     |     | 672 |
| His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln Ala |     |     |     |
| 210   | 215 | 220 |     |
| ctg gcg cgg cag ctg gac gtg ttt ggg cag gcc acc gca gtg ctg cgc |     |     | 720 |
| Leu Ala Arg Gln Leu Asp Val Phe Gly Gln Ala Thr Ala Val Leu Arg |     |     |     |
| 225   | 230 | 235 | 240 |
| tca agg gac ctg ggc tct gtg gtt tgt gac atc aag ttc tca gag ctc |     |     | 768 |
| Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu Leu |     |     |     |
| 245   | 250 | 255 |     |
| tcc tat ctg gac gcc ttc tgg ggc gac tac ctg agt ggc gcc ctg ctg |     |     | 816 |

Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu Leu  
 260 265 270

cag gcc ctg cgg ggc gtg ttc ctg act gag gcc ctg cga gag gct gtg 864  
 Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala Val  
 275 280 285

ggc cg<sup>g</sup> gag gct gtt cgc ctg ctg gtc agt gtg gat gag gct gac 909  
 Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp  
 290 295 300

<210> 2

<211> 303

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp Glu  
 1 5 10 15

Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu Val  
 20 25 30

Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Leu Ala Phe Leu  
 35 40 45

Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg Ser  
 50 55 60

Gly Leu Glu Leu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly Glu  
 65 70 75 80

Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg His  
 85 90 95

Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser Pro  
 100 105 110

Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Ser Lys Arg Thr Glu Gly  
 115 120 125

Ser Cys Arg Arg Arg Gln Ser Ser Ser Ser Ala Asn Ser Gln Gln  
 130 135 140

Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg Ser  
 145 150 155 160

Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala Pro  
 165 170 175

Ala Ala Pro Gln Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu Gly  
 180 185 190

Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys Glu  
 195 200 205

His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln Ala  
 210 215 220

Leu Ala Arg Gln Leu Asp Val Phe Gly Gln Ala Thr Ala Val Leu Arg  
 225 230 235 240

Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu Leu  
 245 250 255

Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu Leu  
 260 265 270

Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala Val  
 275 280 285

Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp  
 290 295 300

<210> 3

<211> 1883

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (124)..(1101)

<400> 3

aggcgtaata atagagaagg tgccagaaaat atccaaaaca agtggctgcg gccgtcgccc 60

aggagtcatc ggacgcccaga atctggccgg gttctgagct tggccgcct ccctcccccg 120

gga atg gcg cta tcc ggg tcg acc ccg gcc ccg tgc tgg gag gag gat 168  
 Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp  
 1 5 10 15

gag tgc ctg gac tac tac ggg atg ctg tgc ctt cac cgt atg ttc gag 216  
 Glu Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu

| 20  | 25  | 30  |     |
|---|-----|-----|-----|
| gtg gtg ggc ggg caa ctg acc gag tgc gag ctg gag ctc ctg gcc ttt<br>Val Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Ala Phe      |     |     | 264 |
| 35  | 40  | 45  |     |
| ctg ctg gat gag gct cct ggc gcc gca gga ggc tta gcc cgcc ggc cgc<br>Leu Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg |     |     | 312 |
| 50  | 55  | 60  |     |
| agc ggc cta gag ctc ctg ctg gag ctg gag cgc cgc ggg cag tgc ggc<br>Ser Gly Leu Glu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly      |     |     | 360 |
| 65  | 70  | 75  |     |
| gag agc aac ctg cgg ctg ctg ggg caa ctc ctg cgc gtg ctg gcc cgc<br>Glu Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg  |     |     | 408 |
| 80  | 85  | 90  | 95  |
| cac gac ctg ctg ccg cac ctg gcg cgc aag cgg cgc cgg cca gtg tct<br>His Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser  |     |     | 456 |
| 100   | 105 | 110 |     |
| cca gaa cgc tat agc tat ggc acc tcc agc tct tca aag agg aca gag<br>Pro Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Ser Lys Arg Thr Glu  |     |     | 504 |
| 115   | 120 | 125 |     |
| ggt agc tgc cgt cgc cgt cgg cag tca agc agt tct gca aat tct cag<br>Gly Ser Cys Arg Arg Arg Arg Gln Ser Ser Ser Ser Ala Asn Ser Gln  |     |     | 552 |
| 130   | 135 | 140 |     |
| cag ggt cag tgg gag aca ggc tcc ccc cca acc aag cgg cag cgg cgg<br>Gln Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg  |     |     | 600 |
| 145   | 150 | 155 |     |
| agt cgg ggc cgg ccc agt ggt ggt gcc aga cgg cgg cgg aga ggg gcc<br>Ser Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala  |     |     | 648 |
| 160   | 165 | 170 | 175 |
| cca gcc gca ccc cag cag cag tca gag ccc gcc aga cct tcc tct gaa<br>Pro Ala Ala Pro Gln Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu  |     |     | 696 |
| 180   | 185 | 190 |     |
| ggc aaa gtg acc tgt gac atc cgg ctc cgg gtt cga gca gag tac tgc<br>Gly Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys  |     |     | 744 |
| 195   | 200 | 205 |     |
| gag cat ggg cca gcc ttg gag cag ggc gtg gca tcc cgg cgg ccc cag<br>Glu His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln  |     |     | 792 |

|  |     |     |      |
|--|-----|-----|------|
| 210  | 215 | 220 |      |
| gcg ctg gcg cgg cag ctg gac gtg ttt ggg cag gcc acc gca gtg ctg<br>Ala Leu Ala Arg Gln Leu Asp Val Phe Gly Gln Ala Thr Ala Val Leu |     |     | 840  |
| 225  | 230 | 235 |      |
| cgc tca agg gac ctg ggc tct gtg gtt tgt gac atc aag ttc tca gag<br>Arg Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu |     |     | 888  |
| 240  | 245 | 250 | 255  |
| ctc tcc tat ctg gac gcc ttc tgg ggc gac tac ctg agt ggc gcc ctg<br>Leu Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu |     |     | 936  |
| 260  | 265 | 270 |      |
| ctg cag gcc ctg cgg ggc gtg ttc ctg act gag gcc ctg cga gag gct<br>Leu Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala |     |     | 984  |
| 275  | 280 | 285 |      |
| gtg ggc cgg gag gct gtt cgc ctg ctg gtc agt gtg gat gag gct gac<br>Val Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp |     |     | 1032 |
| 290  | 295 | 300 |      |
| tat gag gct ggc cgg cgc ctg ttg ctg atg gag gag gaa ggg ggg<br>Tyr Glu Ala Gly Arg Arg Leu Leu Leu Met Glu Glu Glu Gly Gly         |     |     | 1080 |
| 305  | 310 | 315 |      |
| cgc cgc ccg aca gag gcc tcc tgatccagga ctggcaggat tgatcccacc<br>Arg Arg Pro Thr Glu Ala Ser  |     |     | 1131 |
| 320  | 325 |     |      |
| tccaaagtctc cgggccacct tctccctggga ggacgaccat ctctaccct tgacagcccc 1191  |     |     |      |
| tcccacagga tggggctct gaggcctaaa ccattccag ctgagttcc ttcccaagact 1251   |     |     |      |
| cctcctaccc ccaggtgtgc ccccttagcc tccggaggcg gggctgggc ctgtatctca 1311  |     |     |      |
| gaagggaggg gcacagctac acactcacca aaggcccccc tgcacattgt atctctgatc 1371   |     |     |      |
| ttgggctgtc tgcactgtca caggtgcaca cactcgctca tgctcacact gcccctgctg 1431   |     |     |      |
| agatcttccc tgggcctctg ccctggctg cttcccaagca cacacttctt tggctaagg 1491  |     |     |      |
| gcttctctct caggacacct aatttgacca caaccaacct gggcttcagc cacatcagtg 1551   |     |     |      |
| ggcactggag ctggggtgca catggggct gctcacctt cccacacatc tccagccagc 1611   |     |     |      |
| cagggccctg cccagcttca attacagac ctgactctcc tcacccccc ccctgtgtc 1671  |     |     |      |

cagagctgaa catagacttg cacttggat tcacctggag tgtcacatgg gagtgttatg 1731  
gcagcatcat accaaggcct actgttgac atggggccaa aaccagtaaa cagccacctt 1791  
cttggaaagg gaatgcaaag gctttgggg tgatggaaaa gacctttac aaatgatacc 1851  
aattaaactg ccctggaaag ggcataagggtt gg 1883

<210> 4  
<211> 326  
<212> PRT  
<213> *Homo sapiens*

<400> 4  
 Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp Glu  
 1 5 10 15  
  
 Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu Val  
 20 25 30  
  
 Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Leu Ala Phe Leu  
 35 40 45  
  
 Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg Ser  
 50 55 60  
  
 Gly Leu Glu Leu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly Glu  
 65 70 75 80  
  
 Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg His  
 85 90 95  
  
 Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser Pro  
 100 105 110  
  
 Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Ser Lys Arg Thr Glu Gly  
 115 120 125  
  
 Ser Cys Arg Arg Arg Arg Gln Ser Ser Ser Ser Ala Asn Ser Gln Gln  
 130 135 140  
  
 Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg Ser  
 145 150 155 160  
  
 Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala Pro  
 165 170 175

Ala Ala Pro Gln Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu Gly  
                  180                 185                 190  
 Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys Glu  
                  195                 200                 205  
 His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln Ala  
                  210                 215                 220  
 Leu Ala Arg Gln Leu Asp Val Phe Gly Gln Ala Thr Ala Val Leu Arg  
                  225                 230                 235                 240  
 Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu Leu  
                  245                 250                 255  
 Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu Leu  
                  260                 265                 270  
 Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala Val  
                  275                 280                 285  
 Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp Tyr  
                  290                 295                 300  
 Glu Ala Gly Arg Arg Leu Leu Leu Met Glu Glu Glu Gly Gly Arg  
                  305                 310                 315                 320  
 Arg Pro Thr Glu Ala Ser  
                  325

<210> 5  
 <211> 30  
 <212> RNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Artificially  
 Synthesized Oligo-cap Linker

<400> 5  
 agcaucgagu cggccuuguu ggccuacugg

30

<210> 6  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Artificially  
Synthesized oligo dT primer

<400> 6  
gcggctgaag acggcctatg tggcctttt tttttttt tt

42

<210> 7  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Artificially  
Synthesized Primer Sequence

<400> 7  
agcatcgagt cggccttgtt g

21

<210> 8  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Artificially  
Synthesized Primer Sequence

<400> 8  
gcggctgaag acggcctatg t

21

<210> 9  
<211> 77  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Querry Sequence  
for DED Domain

<400> 9  
Leu Tyr Ser Leu His Arg Met Phe Asp Ile Val Gly Thr His Leu Thr  
1 5 10 15

10

His Arg Asp Val Arg Val Leu Ser Phe Leu Phe Leu Val Asp Val Ile  
20 25 30

Asp Asp His Glu Arg Gly Leu Ile Arg Asn Gly Arg Asp Phe Leu Leu  
35 40 45

Ala Leu Glu Arg Gln Gly Arg Cys Asp Glu Ser Asn Phe Arg Gln Val  
50 55 60

Leu Gln Leu Leu Arg Ile Ile Thr Arg His Asp Leu Leu  
65 70 75

&lt;210&gt; 10

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Artificially  
Synthesized Primer Sequence

&lt;400&gt; 10

tcagtgtgga tgaggctgac

21

&lt;210&gt; 11

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Artificially  
Synthesized Primer Sequence

&lt;400&gt; 11

tgcacctgtc acagtgcaga

20

&lt;210&gt; 12

&lt;211&gt; 17

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Artificially  
Synthesized Primer Sequence

<400> 12  
ggttctgagc ttgttcc

17

<210> 13  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Artificially  
Synthesized Primer Sequence

<400> 13  
tcagtca gcc tcatccacac tga

23



<110> OTA, TOSHIO  
ISOGAI, TAKAO  
NISHIKAWA, TETSUO  
HIO, YURI  
MIYOSHI, SOUSUKE  
SATOH, SUSUMU

<120> APOPTOSIS-ASSOCIATED FACTOR

<130> 217860US0PCT

<140> NEW U.S. PCT APPLICATION

<141> 2002-01-08

<150> JP 11-194179

<151> 1999-07-08

<150> US 60/159,586

<151> 1999-10-18

<160> 13

<170> PatentIn version 3.1

<210> 1

<211> 909

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(909)

<223>

|   |  |  |     |
|---|--|--|-----|
| <400> 1   |  |  | 48  |
| atg gcg cta tcc ggg tgc acc ccg gcc ccg tgc tgg gag gag gat gag |  |  |     |
| Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp Glu |  |  |     |
| 1 5 10 15   |  |  |     |
| tgc ctg gac tac tac ggg atg ctg tcc cac cgt atg ttc gag gag     |  |  | 96  |
| Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu Val |  |  |     |
| 20 25 30  |  |  |     |
| gtg ggc ggg caa ctg acc gag tgc gag ctg gag ctc ctg gcc ttt ctg |  |  | 144 |
| Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Ala Phe Leu     |  |  |     |
| 35 40 45  |  |  |     |
| ctg gat gag gct cct ggc gcc gga ggc tta gcc cgg gcc cgc agc     |  |  | 192 |
| Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg Ser |  |  |     |
| 50 55 60  |  |  |     |
| ggc cta gag ctc ctg gag ctg gag cgc cgc ggg cag tgc ggc gag     |  |  | 240 |
| Gly Leu Glu Leu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly Glu |  |  |     |
| 65 70 75 80   |  |  |     |

|   |     |
|---|-----|
| agc aac ctg cgg ctg ctg ggg caa ctc ctg cgc gtg ctg gcc cgc cac<br>Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg His<br>85 90 95        | 288 |
| gac ctg ctg cgg cac ctg gcg cgc aag cgg cgc cgg cca gtg tct cca<br>Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser Pro<br>100 105 110     | 336 |
| gaa cgc tat agc tat ggc acc tcc agc tct tca aag agg aca gag ggt<br>Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Lys Arg Thr Glu Gly<br>115 120 125         | 384 |
| agc tgc cgt cgc cgt cgg cag tca agc agt tct gca aat tct cag cag<br>Ser Cys Arg Arg Arg Gln Ser Ser Ser Ala Asn Ser Gln Gln<br>130 135 140             | 432 |
| ggg cag tgg gag aca ggc tcc ccc cca acc aag cgg cag cgg cgg agt<br>Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg Ser<br>145 150 155 160 | 480 |
| cgg ggc cgg ccc agt ggt ggt gcc aga cgg cgg cgg aqa ggg gcc cca<br>Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala Pro<br>165 170 175     | 528 |
| gcc gca ccc cag cag tca gag ccc gcc aga cct tcc tct gaa ggc<br>Ala Ala Pro Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu Gly<br>180 185 190             | 576 |
| aaa gtg acc tgt gac atc cgg ctc cgg gtt cga gca gag tac tgc gag<br>Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys Glu<br>195 200 205     | 624 |
| cat ggg cca gcc ttg gag cag ggc gtg gca tcc cgg cgg ccc cag gcg<br>His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln Ala<br>210 215 220     | 672 |
| ctg gcg cgg cag ctg gac gtg ttt ggg cag gcc acc gca gtg ctg cgc<br>Leu Ala Arg Gln Leu Asp Val Phe Gly Gln Ala Thr Ala Val Leu Arg<br>225 230 235 240 | 720 |
| tca agg gac ctg ggc tct gtg gtt tgt gac atc aag ttc tca gag ctc<br>Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu Leu<br>245 250 255     | 768 |
| tcc tat ctg gac gcc ttc tgg ggc gac tac ctg agt ggc gcc ctg ctg<br>Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu Leu<br>260 265 270     | 816 |
| cag gcc ctg cgg ggc gtg ttc ctg act gag gcc ctg cga gag gct gtg<br>Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala Val<br>275 280 285     | 864 |
| ggc cgg gag gct gtt cgc ctg ctg gtc agt gtg gat gag gct gag<br>Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp<br>290 295 300             | 909 |

<210> 2  
<211> 303  
<212> PRT  
<213> Homo sapiens

<400> 2

Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp Glu  
1 5 10 15

Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu Val  
20 25 30

Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Leu Ala Phe Leu  
35 40 45

Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg Ser  
50 55 60

Gly Leu Glu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly Glu  
65 70 75 80

Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg His  
85 90 95

Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser Pro  
100 105 110

Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Ser Lys Arg Thr Glu Gly  
115 120 125

Ser Cys Arg Arg Arg Gln Ser Ser Ser Ser Ala Asn Ser Gln Gln  
130 135 140

Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg Ser  
145 150 155 160

Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala Pro  
165 170 175

Ala Ala Pro Gln Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu Gly  
180 185 190

Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys Glu

195

200

205

His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln Ala  
 210 215 220

Leu Ala Arg Gln Leu Asp Val Phe Gly Gln Ala Thr Ala Val Leu Arg  
 225 230 235 240

Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu Leu  
 245 250 255

Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu Leu  
 260 265 270

Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala Val  
 275 280 285

Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp  
 290 295 300

<210> 3  
<211> 1883  
<212> DNA  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (124)..(1101)  
<223>

<400> 3  
aggcgtaata atagagaagg tgccagaaaag atccaaaaca agtggctgct gccgtcgccc 60

aggagtcatc ggacgccaga atctggccgg gttctgagct tggccgcct cccccccccg 120

gga atg gcg cta tcc ggg tcg acc ccg gcc ccg tgc tgg gag gag gat 168  
 Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp  
 1 5 10 15

gag tgc ctg gac tac tac ggg atg ctg tcg ctt cac cgt atg ttc gag 216  
 Glu Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu  
 20 25 30

gtg gtg ggc ggg caa ctg acc gag tgc gag ctg gag ctc ctg gcc ttt 264  
 Val Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Ala Phe  
 35 40 45

ctg ctg gat gag gct cct ggc gcc gca ggc tta gcc cggttggcccgcc 312  
 Leu Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg

|  | 50  | 55  | 60  |     |
|--|-----|-----|-----|-----|
| agc ggc cta gag ctc ctg ctg gag ctg gag cgc cgc ggg cag tgc ggc<br>Ser Gly Leu Glu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly         | 65  | 70  | 75  | 360 |
| gag agc aac ctg cgg ctg ctg ggg caa ctc ctg cgc gtg ctg gcc cgc<br>Glu Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg     | 80  | 85  | 90  | 408 |
| cac gac ctg ctg ccg cac ctg gcg cgc aag cgg cgc cgg cca gtg tct<br>His Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser     | 100 | 105 | 110 | 456 |
| cca gaa cgc tat agc tat ggc acc tcc agc tct tca aag agg aca gag<br>Pro Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Lys Arg Thr Glu         | 115 | 120 | 125 | 504 |
| ggt agc tgc cgt cgc cgt cgg cag tca agc agt tct qca aat tct cag<br>Gly Ser Cys Arg Arg Arg Arg Gln Ser Ser Ser Ala Asn Ser Gln         | 130 | 135 | 140 | 552 |
| cag ggt cag tgg gag aca ggc tcc ccc cca acc aag cgg cag cgg cgg<br>Gln Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg     | 145 | 150 | 155 | 600 |
| agt cgg ggc cgg ccc agt ggt ggt gcc aga cgg cgg cgg aga ggg gcc<br>Ser Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala     | 160 | 165 | 170 | 648 |
| cca gcc gca ccc cag cag cag tca gag ccc gcc aga cct tcc tct gaa<br>Pro Ala Ala Pro Gln Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu     | 180 | 185 | 190 | 696 |
| ggc aaa gtg acc tgt gac atc cgg ctc cgg gtt cga gca gag tac tac tgc<br>Gly Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys | 195 | 200 | 205 | 744 |
| gag cat ggg cca gcc ttg qag caq qgc qtg gca tcc cgg cgg ccc cag<br>Glu His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln     | 210 | 215 | 220 | 792 |
| gcg ctg gcg cgg cag ctg gac gtg ttt ggg cag gcc acc gca gtg ctg<br>Ala Leu Ala Arg Gln Leu Asp Val Phe Gln Ala Thr Ala Val Leu         | 225 | 230 | 235 | 840 |
| cgc tca agg gac ctg ggc tct qtg gtt tgt gac atc aag ttc tca gag<br>Arg Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu     | 240 | 245 | 250 | 888 |
| ctc tcc tat ctg gac gcc ttc tgg ggc gac tac ctg agt ggc gcc ctg<br>Leu Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu     | 260 | 265 | 270 | 936 |
| ctg cag gcc ctg cgg ggc gtg ttc ctg act gag gcc ctg cga gag gct<br>Leu Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala     | 275 | 280 | 285 | 984 |

|  |      |
|--|------|
| gtg ggc cgg gag gct gtt cgc ctg ctg gtc agt gtg gat gag gct gac<br>Val Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp | 1032 |
| 290 295 300  |      |
| tat gag gct ggc cgg cgc cgc ctg ttg ctg atg gag gag gaa ggg ggg<br>Tyr Glu Ala Gly Arg Arg Leu Leu Leu Met Glu Glu Glu Gly Gly     | 1080 |
| 305 310 315  |      |
| cgg cgc ccg aca gag gcc tcc tgatccagga ctggcaggat tgatcccc<br>Arg Arg Pro Thr Glu Ala Ser  | 1131 |
| 320 325  |      |
| tccaaagtctc cggggcacct ttcctctggga ggacgaccat ctctacccct tgacagcccc  | 1191 |
| tcccacagga tggggctct gaggctaaa ccattccag ctgagttcc ttcccgact   | 1251 |
| cctctatccc ccagggtgtc ccccttagcc tccggaggcg ggggctggc ctgtatctca   | 1311 |
| gaagggaggg gcacagctac acactcacca aagggccccc tgcacattgt atctctgtac  | 1371 |
| ttgggctgtc tgcactgtca caggtgcaca cactcgctca tgctcacact gcccctgtcg  | 1431 |
| agatcttccc tgggctctg ccctggctg cttcccagca cacacttctt tggcctaagg  | 1491 |
| gttctctct caggacactt aatttgacca caaccaacct gggcttcagc cacatcagtg   | 1551 |
| ggcactggag ctggggtgca catggggcct gtcacatttgc cccacacatc tccagccagc   | 1611 |
| cagggccctg cccagcttca atttacagac ctgactctcc tcaccttccc ccctgtgtc   | 1671 |
| cagagctgaa catagacttgc actttggatg tcacctggag tgtcacatgg gagtgttatg   | 1731 |
| gcagcatcat accaaggctt actgttgac atggggccaa aaccagtaaa cagccacctt   | 1791 |
| cttggaaagg gaatgaaag gttttgggg tgatggaaaa gacctttac aaatgataacc  | 1851 |
| aattaaactg ccctggaaag ggcataagg 4  | 1883 |

<210> 4  
<211> 326  
<212> PRT  
<213> Homo sapiens

<400> 4

|   |  |
|---|--|
| Met Ala Leu Ser Gly Ser Thr Pro Ala Pro Cys Trp Glu Glu Asp Glu |  |
| 1 5 10 15   |  |

|   |  |
|---|--|
| Cys Leu Asp Tyr Tyr Gly Met Leu Ser Leu His Arg Met Phe Glu Val |  |
| 20 25 30  |  |

|   |  |
|---|--|
| Val Gly Gly Gln Leu Thr Glu Cys Glu Leu Glu Leu Leu Ala Phe Leu |  |
| 35 40 45  |  |

Leu Asp Glu Ala Pro Gly Ala Ala Gly Gly Leu Ala Arg Ala Arg Ser  
 50 55 60

Gly Leu Glu Leu Leu Leu Glu Leu Glu Arg Arg Gly Gln Cys Gly Glu  
 65 70 75 80

Ser Asn Leu Arg Leu Leu Gly Gln Leu Leu Arg Val Leu Ala Arg His  
 85 90 95

Asp Leu Leu Pro His Leu Ala Arg Lys Arg Arg Arg Pro Val Ser Pro  
 100 105 110

Glu Arg Tyr Ser Tyr Gly Thr Ser Ser Ser Ser Lys Arg Thr Glu Gly  
 115 120 125

Ser Cys Arg Arg Arg Arg Gln Ser Ser Ser Ser Ala Asn Ser Gln Gln  
 130 135 140

Gly Gln Trp Glu Thr Gly Ser Pro Pro Thr Lys Arg Gln Arg Arg Ser  
 145 150 155 160

Arg Gly Arg Pro Ser Gly Gly Ala Arg Arg Arg Arg Arg Gly Ala Pro  
 165 170 175

Ala Ala Pro Gln Gln Gln Ser Glu Pro Ala Arg Pro Ser Ser Glu Gly  
 180 185 190

Lys Val Thr Cys Asp Ile Arg Leu Arg Val Arg Ala Glu Tyr Cys Glu  
 195 200 205

His Gly Pro Ala Leu Glu Gln Gly Val Ala Ser Arg Arg Pro Gln Ala  
 210 215 220

Leu Ala Arg Gln Leu Asp Val Phe Gly Gln Ala Thr Ala Val Leu Arg  
 225 230 235 240

Ser Arg Asp Leu Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu Leu  
 245 250 255

Ser Tyr Leu Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu Leu  
 260 265 270

Gln Ala Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala Val  
275 280 285

Gly Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp Tyr  
290 295 300

Glu Ala Gly Arg Arg Arg Leu Leu Leu Met Glu Glu Glu Gly Gly Arg  
305 310 315 320

Arg Pro Thr Glu Ala Ser  
325

<210> 5  
<211> 30  
<212> RNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC RNA

<400> 5  
agcaucgagu cggccuuuguu ggccuacugg

30

<210> 6  
<211> 42  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC DNA

<400> 6  
gcggctgaaq acggcctatg tggcctttt ttttttttt tt

43

<210> 7  
<211> 21  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC DNA

<400> 7  
agcatcgagt cggccttgtt q

21

<210> 8  
<211> 21  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC DNA

<400> 8  
gcggctgaag acggcctatg t

21

<210> 9  
<211> 77  
<212> PRT  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC PEPTIDE

<400> 9

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Tyr | Ser | Leu | His | Arg | Met | Phe | Asp | Ile | Val | Gly | Thr | His | Leu | Thr |
| 1   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|     |     |     |     |     |     | 5   |     |     |     | 10  |     |     |     |     | 15  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Arg | Asp | Val | Arg | Val | Leu | Ser | Phe | Leu | Phe | Leu | Val | Asp | Val | Ile |
|     |     |     | 20  |     |     |     |     |     |     |     |     |     |     |     | 30  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Asp | His | Glu | Arg | Gly | Leu | Ile | Arg | Asn | Gly | Arg | Asp | Phe | Leu | Leu |
|     |     |     | 35  |     |     |     |     |     |     |     |     |     |     |     | 45  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Leu | Glu | Arg | Gln | Gly | Arg | Cys | Asp | Glu | Ser | Asn | Phe | Arg | Gln | Val |
|     |     |     |     | 50  |     |     |     |     |     |     |     |     |     |     | 60  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Gln | Leu | Leu | Arg | Ile | Ile | Thr | Arg | His | Asp | Leu | Leu |
|     |     |     |     |     |     | 70  |     |     |     |     |     | 75  |

<210> 10  
<211> 21  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC DNA

<400> 10  
tcagtgtgaa tgaggctgac t

21

<210> 11  
<211> 20  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC DNA

<400> 11  
tgcacctgtg acagtgacaga 20

<210> 12  
<211> 17  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC DNA

<400> 12  
ggttctgatc ttgttcc 17

<210> 13  
<211> 23  
<212> DNA  
<213> ARTIFICIAL SEQUENCE

<220>  
<223> SYNTHETIC DNA

<400> 13  
tcagtcaacc tcataccacac tga 23